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In August 2015 the German Standing on 
Vaccination (STIKO) endorsed a recom-
mendation for the use of the new menin-
gococcal B (menB) vaccine in persons at 
increased risk of invasive meningococcal 
disease (IMD). This background paper 
presents in detail the results of the litera-
ture reviews and the grading of the quali-
ty of the available evidence underlying the 
new STIKO recommendations. The docu- 
ment opens with a brief synthesis for rap-
id orientation. A German version of this 
background paper is available in the Epi-
demiologische Bulletin 37/2015 [1].
1  Summary
A surface protein-based vaccine against 
serogroup B became available in Decem-
ber 2013 (BexseroÒ; called 4CMenB in li-
censure studies) to complement the poly-
saccharide capsule-based conjugate vac-
cines against serogroups A, C, W and Y 
(MenACWY) previously available.
Following evaluation of the available 
evidence, the German Standing Commit-
tee on Vaccination [Ständige Impfkom-
mission, STIKO] recommends MenB 
vaccination for the following persons at 
increased risk of IMD after individual 
risk assessment. Persons at increased risk 
of IMD due to congenital or acquired im-
mune deficiency or suppression with re-
sidual T and/or B cell function, particular-
ly in cases of complement/properdin de-
ficiency, eculizumab therapy (monoclo-
nal antibody against the terminal com-
plement component C5), hypogamma-
globulinemia and anatomical or func-
tional asplenia should be vaccinated with 
a MenB vaccine in addition to a meningo-
coccal ACWY conjugate vaccine (see cur-
rent STIKO recommendations, Epid. Bull. 
34/2015). Likewise, household or house-
hold-like contacts of a patient with inva-
sive meningococcal disease (IMD) should 
receive post-exposure vaccination, not 
only when IMD in the index patient is 
caused by serogroups A, C, W or Y, but 
now also when caused by serogroup B. Fi-
nally, at-risk laboratory staff (performing 
work procedures with a risk of N. menin­
gitidis aerosol formation) should receive 
MenB vaccination in addition to vacci-
nation with a MenACWY conjugate vac-
cine.
The incidence of IMD in Germany 
has decreased markedly since introduc-
tion of mandatory reporting in 2001, to 
an overall annual incidence of 0.44 IMD 
cases/100,000 inhabitants (Inh.) in 2010–
2013. This corresponds to 250 cases of 
MenB, 78 MenC and 35 cases due to oth-
er serogroups annually. The proportion 
of IMD cases in persons at increased risk 
due to underlying medical conditions or 
through close contact with IMD patients 
is largely unknown. Clusters of IMD cas-
es due to the same meningococcal strain 
are rare (< 2 % of all cases), usually affect-
ing only a few persons often living togeth-
er in one household.
No data are available on the efficacy 
of BexseroÒ against clinical outcomes. A 
preliminary review of available licensure 
studies was performed to assess data on 
immunogenicity. Results based on bac-
tericidal antibodies (hSBA) against the 
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four antigens present in the vaccine mea-
sured after vaccination are consistent with 
very good efficacy against infections with 
strains susceptible to the induced antibod-
ies shortly after vaccination in infants (4 
vaccine doses) and toddlers (2–3 vaccine 
doses), with a marked decline in hSBA af-
ter 1 year. Likewise, very good immuno-
genicity was observed after 2 vaccine dos-
es in adolescents with more stable persis-
tence of protective hSBA 18–24 months af-
ter vaccination (. Annex 1), although the 
hSBA GMT (geometric mean titer) de-
clined by an order of magnitude in this 
time period. No data were available on 
immunogenicity in persons with chron-
ic diseases or immune deficiencies/immu-
nosuppression. Based on data on immune 
responses to other vaccines, the effective-
ness and duration of protection in indi-
viduals with immune deficiencies/immu-
nosuppression are likely to be lower than 
in healthy persons. The 4CMenB vaccine 
(BexseroÒ) cannot prevent all infections 
with MenB strains, as only 82 % of the me-
ningococcal strains circulating in Germa-
ny expressed at least one of the vaccine an-
tigens in 2007–2008.
Reactogenicity and safety of the 
4CMenB vaccine were evaluated in de-
tail in accordance with the STIKO Stand-
ing operating procedure (SOP) (see An-
nex 2). Briefly, the randomized studies 
identified for this evaluation had critical 
methodological flaws that led to down-
grading of the evidence level in accor-
dance with GRADE (Grading of Recom­
mendations Assessment, Development 
and Evaluation) methodology to “low” 
or “very low”. Very rare, potentially se-
vere adverse effects could not be evaluat-
ed based on insufficient numbers of cases 
included. In infants particularly, the avail-
able data showed a significantly increased 
risk for febrile reactions, especially when 
4CMenB was administered simultaneous-
ly with the routine vaccinations Infanrix 
hexaÒ and PrevenarÒ (> 70 %, compared 
to 40 % following administration of the 
routine vaccinations alone). An approxi-
mately 4- to 5-fold increased risk of severe 
tenderness was also seen in infants follow-
ing 4CMenB (in 13–29 % of those vacci-
nated). Fever was shown to occur signifi-
cantly more frequently in adolescents, but 
not in adults, following 4CMenB vaccina-
tion (3.7 %) compared to placebo (1.6 %). 
Severe local pain and headache also oc-
curred significantly more frequently in 
adolescents and adults following 4CMenB 
vaccination. The spectrum of adverse 
events based on available data from post-
marketing surveillance was similar to that 
based on licensure studies.
The results of narrative literature re-
views showed a markedly increased risk 
of IMD for persons with complement de-
ficiencies (esp. terminal deficiencies and 
properdin deficiency), but only a slight in-
crease in absolute risk of disease for per-
sons with asplenia and only a marginal-
ly increased risk with other immune defi-
ciencies (see . Tables 1 and 2). Based on 
these estimates as well as on the estimat-
ed vaccine effectiveness (VE), a relatively 
low number of persons with complement 
deficiencies (49–98) compared to those 
with asplenia (approximately 19,000) was 
estimated to require MenB vaccination to 
prevent a single case of IMD in the year af-
ter the vaccination. For persons with other 
immune deficiencies, the NNV was high-
er still than for asplenia (see . Tables 1 
and 2). However, because of the severi-
ty of IMD and the immunological plausi-
bility for an elevated IMD risk in persons 
with the immune deficiencies/immuno-
suppression considered here, STIKO rec-
ommends both MenACWY and MenB 
vaccination for affected persons based on 
an individual risk assessment.
Household contacts of persons with 
IMD have an approximately 100-fold in-
creased risk of contracting IMD in the 
ensuing year despite post-exposure che-
moprophylaxis [2]. Therefore, STIKO 
recommended vaccination with a Men-
ACWY conjugate vaccine in 2009 for 
contacts of index cases due to these se-
rogroups [3]. In view of the severity of 
IMD, STIKO recommends vaccination 
of household contacts of serogroup IMD 
cases based on an individual risk assess-
ment despite the likely lower VE of Bex-
seroÒ compared to the conjugate vac-
Table 1 Summary of the estimates for the risk of invasive meningococcal disease due to serogroup B in selected risk groups and the estimated 
number of respective individuals needed to be vaccinated with Bexsero® to prevent one case (number needed to vaccinate, NNV). See text for 
details of the calculations with underlying assumptions
Risk group (esti-
mated number of 
affected persons in 
Germany)






In the year after vaccination Within 3 years after vaccination




coverage = 100 %





coverage = 100 %
Asplenia (90,000) 8 7.2 19,000 4.7 6350 14.2
Complement defi-
ciencies (8–10,000)
1550–3100 155–310 49–98 102–204 16–32 306–612d
HIV infectionsc 
(80,000)
1.5–3.0 1.2–2.4 51,000–102,000 1.2–2.3 13,900–27,800 2.9–5.9
Immune deficiencies 





not estimated Similar to HIV-in-
fected individuals
not estimated Similar to HIV-in-
fected individuals
not estimated
aAssumption: Average term of protection of the vaccination is 1 year or b3 years.
cEstimate performed for an estimated 10.000 affected.
dThese calculations clarify the uncertainty regarding the estimate of the number of affected persons in Germany: In the group of complement deficiencies, the maximum 
estimate of 10,000 appears excessive; as, based on the 5000–10,000-fold increased risk of IMD, the majority of persons with IMD in Germany would have to have a comple-
ment deficiency.
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cines (see below). Besides the possibility 
that the household might be situated in a 
social setting with ongoing circulation of 
pathogenic meningococci, family mem-
bers might also have a genetic predisposi-
tion for an increased IMD risk that could 
be reduced by vaccination. Rapid sero-
group identification and prompt vacci-
nation is critical for early protection, as 
approximately 70 % of the late secondary 
cases occur in the first 3 months following 
contact with the index case.
Laboratory personnel at risk of expo-
sure to N. meningitidis aerosols is also rec-
ommended to receive a MenB vaccine in 
addition to a MenACWY vaccine since 
they are at increased risk of IMD com-
pared to the general population [4, 5]. 
While such cases can be avoided through 
appropriate safety precautions (class II 
safety workbench; respiratory protection 
in the case of aerosol formation), human 
error or laboratory accidents can never be 
completely avoided.
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Abstract
In December 2013 Bexsero® became avail-
able in Germany for vaccination against se-
rogroup B meningococci (MenB). In August 
2015 the German Standing Committee on 
Vaccination (STIKO) endorsed a recommen-
dation for use of this vaccine in persons at in-
creased risk of invasive meningococcal dis-
ease (IMD). This background paper summa-
rizes the evidence underlying the recommen-
dation. Bexsero® is based on surface protein 
antigens expressed by about 80 % of circulat-
ing serogroup B meningococci in Germany. 
The paper reviews available data on immu-
nogenicity and safety of Bexsero® in healthy 
children and adolescents; data in persons 
with underlying illness and on the effective-
ness in preventing clinical outcomes are thus 
far unavailable.
STIKO recommends MenB vaccination for 
the following persons based on an individual 
risk assessment: (1) Persons with congenital 
or acquired immune deficiency or suppres-
sion. Among these, persons with terminal 
complement defects and properdin deficien-
cy, including those under eculizumab ther-
apy, are at highest risk with reported inva-
sive meningococcal disease (IMD) incidenc-
es up 10,000-fold higher than in the gener-
al population. Persons with asplenia were es-
timated to have a ~ 20–30-fold increased risk 
of IMD, while the risk in individuals with oth-
er immune defects such as HIV infection or 
hypogammaglobulinaemia was estimated 
at no more than 5–10-fold higher than the 
background risk. (2) Laboratory staff with a 
risk of exposure to N. meningitidis aerosols, 
for whom an up to 271-fold increased risk 
for IMD has been reported. (3) Unvaccinated 
household (-like) contacts of a MenB IMD in-
dex case, who have a roughly 100–200-fold 
increased IMD risk in the year after the con-
tact despite chemoprophylaxis. Because the 
risk is highest in the first 3 months and full 
protective immunity requires more than one 
dose (particularly in infants and toddlers), 
MenB vaccine should be administered as 
soon as possible following identification of 
the serogroup of the index case.
Keywords
Neisseria meningitidis · Meningococcal 
group B vaccination · Germany · Vaccination 
recommendation · Prevention
Wissenschaftliche Begründung zur Aktualisierung der Meningokokken-
Impfempfehlung – Anwendung des Meningokokken-B-Impfstoffs bei 
Personen mit erhöhtem Risiko für Meningokokken-Erkrankungen
Zusammenfassung
Seit Dezember 2013 ist der Impfstoff Bexse-
ro® zum Schutz vor Meningokokken der Se-
rogruppe B (MenB) in Deutschland verfüg-
bar. Seit August 2015 empfiehlt die Ständige 
Impfkommission (STIKO) die Anwendung die-
ser Impfung bei Personen mit erhöhtem Risi-
ko für Meningokokken-Erkrankungen. Diese 
Begründung fasst die Evidenz zusammen, die 
der STIKO-Empfehlung zugrunde lag. Bex-
sero® basiert auf Oberflächenproteinantige-
nen, die von ca. 80 % der in Deutschland zir-
kulierenden MenB-Stämme exprimiert wer-
den. Es wird ein Überblick über die Immuno-
genität und Sicherheit des Impfstoffs bei ge-
sunden Kindern und Jugendlichen präsen-
tiert; entsprechende Daten von Personen mit 
Grunderkrankungen sowie zur Wirksamkeit 
in Bezug auf Schutz vor klinischen Endpunk-
ten stehen derzeit noch aus.
Die STIKO empfiehlt eine Impfung mit 
Bexsero® nach individueller Risikoabschät-
zung für folgende Personen: 1) Gesund-
heitlich gefährdete Personen mit angeboren-
er oder erworbener Immundefizienz bzw. 
-suppression. Von diesen haben Personen 
mit terminalen Komplementdefekten, ein-
schließlich bei Therapie mit Eculizumab, sow-
ie mit Properdindefizienz, das höchste Risiko 
für eine invasive Meningokokken-Erkrankung 
(IME); es liegt bis zu 10.000-fach höher als in 
der Allgemeinbevölkerung. Das Erkrankung-
srisiko für Personen mit Asplenie ist ca. 20- 
bis 30-fach erhöht und liegt für Personen mit 
anderen Immundefekten, z. B. mit HIV-Infek-
tion oder Hypogammaglobulinämie wahrs-
cheinlich nicht mehr als 5- bis 10-fach er-
höht gegenüber der Hintergrundinzidenz. 
2) Laborpersonal, das ein Risiko für Kontakt 
mit N.-meningitidis-Aerosolen hat. Für diese 
Gruppe wurde ein bis zu 271-fach erhöhtes 
Risiko für IME berichtet. 3) Ungeimpfte Haus-
haltskontakte oder enge Kontakte mit haush-
altsähnlichem Charakter einer Person mit ein-
er IME durch MenB. Diese haben trotz Erhalt 
einer Chemoprophylaxe ein ca. 100–200-fach 
erhöhtes Risiko für IME in den 14 bis 365 Ta-
gen nach dem Kontakt, wobei das Risiko in 
den ersten 3 Monaten am höchsten ist. Da-
her, und weil der vollständige Impfschutz ins-
besondere bei Säuglingen und Kleinkindern 
mehrere Impfdosen benötigt, sollte die 
MenB-Impfung der Kontaktperson so bald 




Impfung · Deutschland · Impfempfehlung · 
Prävention
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The possible implementation of MenB 
vaccination in the control of clusters or 
outbreaks of menB disease was not spe-
cifically addressed, as existing STIKO rec-
ommendations outline the course of ac-
tion for all serogroups, see p. 334 of the 
current STIKO recommendations (Epid 
Bull 34/2015).
To ensure adequate MenB surveillance 
and evaluation of the current vaccine rec-
ommendations, it is crucial that menin-
gococcal strains isolated from patients be 
sent to the National Reference Center for 
Meningococci and Haemophilus influen­
zae [Nationales Referenzzentrum für Me-
ningokokken und Haemophilus influen­
zae (NRZMHi)] for further character-
ization. In particular, only further char-
acterization at NRZMHi can determine 
whether a MenB strain should or should 
not have been covered by the 4CMenB 
vaccine. This is essential for identifying 
vaccine breakthroughs and estimating 
VE. Notifications according to the Infec-
tion Against Protection Act [Infektions-
schutzgesetz (IfSG)] do not include in-
formation on a patient’s potentially in-
creased IMD risk due to underlying ill-
ness/immune deficiency as specified by 
STIKO or whether the person was infect-
ed in a laboratory setting. Thus, the im-
pact of the MenB vaccination recommen-
dation for risk groups cannot be evaluated 
systematically on the basis of routine no-
tification data.
Finally, according to the Summary of 
Product Characteristics [6], BexseroÒ is 
subject to additional monitoring. As stip-
ulated by the European Medicines Agen-
cy (EMA) in its Assessment Report [7], 
this includes further studies on safety and 
clinical efficacy as well as immunogenicity 
in persons with complement deficiencies. 
Health professionals in Germany are re-
quired in the Summary of Product Char-
acteristics to report every suspected case 
of an adverse reaction due to BexseroÒ to 
the Paul Ehrlich Institute (PEI). Accord-
ing to § 6 para. 1, no. 3 IfSG, all suspect-
ed cases of health impairment exceeding 
the usual severity of a vaccination reaction 
should be reported to PEI.
2  Introduction and objectives
An increased risk of invasive infection 
with Neisseria meningitidis (Nm) was re-
ported for individuals with certain types 
of immune deficiency or suppression, par-
ticularly for those with congenital com-
plement deficiencies or those undergoing 
complement-neutralizing antibody ther-
apy with eculizumab, but also those with 
asplenia, or hypoglobulinemia [8–11]. In 
addition, an increased risk for household 
contacts was observed within a one-year 
period after contact with an IMD index 
case, even after they had received chemo-
prophylaxis [2]. Finally, laboratory staff at 
risk for contact with N. meningitidis aero-
sols also has an increased risk of disease 
compared to the general population [4, 5].
Until August 2015, STIKO recom-
mended vaccination with a tetravalent 
ACWY conjugate vaccine for individu-
als at increased risk for IMD due to con-
genital or acquired immune deficiency or 
suppression with residual T and/or B cell 
function, particularly complement/pro-
perdin deficiencies, hypogammaglobu-
linemia, functional or anatomical asple-
nia, provided the vaccine is licensed for 
the age group. Additionally, STIKO rec-
ommended MenACWY vaccination for 
household or household-like contacts 
of patients with IMD due to these sero-
groups and for laboratory staff at risk of 
Table 2 Summary of the estimates for the risk of invasive meningococcal disease due to serogroups C, W or Y in selected risk groups and the 
estimated number of respective individuals needed to be vaccinated against MenACWY to prevent one case (number needed to vaccinate, NNV). 
See text for details of the calculations with underlying assumptions
Risk group
(estimated number 
of affected persons 
in Germany)






In the year after vaccination Within 3 years after vaccination
NNVa in the year 
after vaccination
Cases prevented 
with a vaccination 
coverage = 100%








4 3.6 31,250 2.9 10,400 8.7
Complement defi-
ciencies (10,000)
650–1300 65–130 96–192 52–104 32–63 159–312d
HIV infectionsc
(80,000)
0.7–1.4 0.6–1.1 89,300–178,600 0.4–0.9 29,800–59,500 1.3–2.7
Immune deficien-





Not estimated Similar to HIV-in-
fected individuals
Not estimated Similar to HIV-in-
fected individuals
Not estimated
aAssumption: Average term of protection of the vaccination is 1 year or b3 years.
cEstimate performed for an estimated 10.000 affected.
dThese calculations clarify the uncertainty regarding the estimate of the number of affected persons in Germany: In the group of complement deficiencies, the maximal esti-
mate of 10,000 appears excessive; as, based on the 5000–10,000-fold increased risk of IMD, the majority of persons with IMD in Germany would have to have a complement 
deficiency.
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contact with N. meningitidis aerosols. A 
vaccine against serogroup B, the 4CMenB 
vaccine (BexseroÒ), additionally became 
available in Germany in December 2013. 
STIKO considered whether these vaccina-
tion recommendations should also apply 
to this vaccine.
3  Immunization goal
The goal of this recommendation is to 
lower the IMD burden due to serogroup 
B in individuals at increased risk of dis-
ease (due to immune deficiency/immu-
nosuppression, household contact or pro-
fessional exposure) through the 4CMenB 
(BexseroÒ) vaccine, available in Germany 
since December 2013.
4  Methods
STIKO’s standing operating procedure 
(SOP) calls for performance of system-
atic reviews for questions on efficacy and 
safety of a vaccine under evaluation and a 
grading of the quality of evidence by ap-
plying the framework of the Grading of 
Recommendations Assessment, Develop­
ment and Evaluation (GRADE) working 
group [1]. Further questions can be con-
sidered by means of narrative reviews. 
Evaluation of the safety of the 4CMenB 
vaccine was performed in accordance 
with the STIKO SOP by means of a sys-
tematic review (see Annex 2). However, 
only a narrative review was performed re-
garding the efficacy of the 4CMenB vac-
cine due to paucity of data—especially for 
individuals with immune deficiencies. A 
systematic evaluation of the efficacy/effec-
tiveness of the 4CMenB vaccine according 
to GRADE will be undertaken for the final 
evaluation of possible routine MenB vac-
cination in infants, as soon as data on the 
protective effect against clinical outcomes 
become available.
To roughly quantify and compare pos-
sible effects of a MenB vaccination for 
specific risk groups, the number of per-
sons who would need to be vaccinated to 
prevent one IMD case (Number needed to 
vaccinate—NNV) was calculated under 
various assumptions of disease risk (IMD 
incidence in the risk group), vaccine effec-
tiveness (VE) and strain coverage. NNV 
was calculated according to the following 
formula [12]:
5  Pathogen
Meningococci are gram-negative bacteria 
of the species Neisseria meningitidis. They 
are divided into 12 serogroups [13], with 
serogroups B (a good two thirds of all cas-
es) and C (approximately one quarter of 
all cases) primarily responsible for IMD 
in Germany. Serogroups Y and W135, by 
contrast, cause only approximately 5 and 
2 % of cases, respectively. Meningococ-
ci are transmitted by respiratory droplet 
infection, e.g. by coughing or sneezing. 
Carriage studies revealed meningococcal 
colonization of the mucous membranes 
in the pharynx in approximately 10 % of 
healthy persons [14]. In certain groups, 
e.g. in adolescents, soldiers in barracks, 
men who have sex with men (MSM), 
markedly higher carriage rates of 20–40 % 
were reported [14–20]. Colonization with 
meningococci only rarely leads to invasive 
disease. This occurs when the pathogen 
infiltrates the mucosal barrier in the ab-
sence of type-specific immunity and is fa-
cilitated through non-specific damage to 
the mucosal membranes (e.g. through vi-
ral infections, dry air or smoking [21–24]).
6  Clinical manifestations
IMD usually manifests clinically as me-
ningococcal meningitis or meningococcal 
sepsis (with or without meningitis). The 
spectrum of clinical manifestation rang-
es from transient asymptomatic bacterae-
mia to a fulminant septic course that can 
lead to death within a few hours (purpura 
fulminans, Waterhouse-Friderichsen syn-
drome [25]). Case fatality in Germany lies 
at 8 % for MenB and 11 % for MenC dis-
ease. It is markedly higher at approximate-
ly 18 % in patients with sepsis, than in those 
with meningitis alone (approximately 2 %). 
About 10–20 % of survivors of an invasive 
meningococcal B disease suffer compli-
cations such as hearing loss, neurological 
damage or amputations [26–29].
7  Epidemiology of 
invasive meningococcal 
diseases in Germany
From 2010 to 2013 on average 364 persons 
were notified with IMD annually (0.44 
cases of disease/100,000 Inh.) in Germa-
ny. Of these, 250 (69 %) were due to se-
rogroup B (0.30 cases of disease/100,000 
Inh./year), 78 (22 %) to serogroup C (0.09 
cases of disease/100,000 Inh./year), and 35 
(10 %) to serogroups A, W, or Y (0.03 cases 
of disease/100,000 Inh./year). The number 
of notified IMD cases decreased markedly 
since 2005; this is particularly due to a de-
cline in cases of MenB and MenC. From 
2001 to 2005, the number of annually no-
tified MenB cases ranged from 400 to 570 
and the number of MenC cases from 130 
to 223. Since 2006, STIKO recommends 
vaccination against MenC for all chil-
dren in the second year of life. Incidence 
of MenC has declined more sharply than 
that of MenB incidence in age groups with 
high vaccination coverage (1–19-year-olds, 
unpublished data, RKI). Infants and tod-
dlers are at highest risk of disease with an 
additional, smaller incidence peak in ad-
olescents aged 15–19 years (see . Fig. 1). 
The proportion of MenB and MenC cas-
es is highest in infants and toddlers, while 
the proportion of MenW and MenY cases 
in adults is markedly higher than in chil-
dren and adolescents (. Fig. 1, insert). 
Less than 2 % of all IMD cases are epide-
miologically linked.
Compared to other European coun-
tries, IMD incidence in Germany is in 
the lowest tertile. For instance, in 2011 the 
incidence of serogroup B disease in in-
fants in Germany was 5.9, in Great Brit-
ain 25.3 and in Ireland 38.6 cases/100,000 
Inh. [30].
Details on the epidemiology of IMD in 
the risk groups under consideration fol-
low in Sect. 9.
8  The vaccine
Following the positive opinion of EMA 
in November 2012, a vaccine against se-
rogroup B meningococci (4CMenB) was 
licensed as BexseroÒ (Novartis Vaccines) 
NNV=
100,000
IMD cases per 100,000 inhabitants
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for the first time in Europe on 22 January 
2013 [7, 31]. BexseroÒ became available in 
Germany in December 2013.
Since the MenB capsule is structurally 
related to a glycolylated embryonic neu-
ronal cellular adhesion protein (NCAM-1) 
[32] and is therefore poorly immunogen-
ic, it could not be used as a vaccine an-
tigen as was possible for serogroups A, 
C,W and Y. Particularly immunogenic 
antigens were identified through reverse 
vaccinology, i.e. computer-based analysis 
of the N. meningitidis genome for poten-
tial surface protein antigens, with subse-
quent antigen expression and immuniza-
tion of mice [33]. Thus, the 4CMenB vac-
cine contains a total of 4 antigen compo-
nents: The first consists of detoxified out-
er membrane vesicles (OMV) that contain 
diverse membrane proteins, Porin A (Po-
rA) being immunodominant. This OMV 
preparation corresponds to the MeNZB™ 
vaccine that was used in New Zealand for 
outbreak control [34]. Two additional an-
tigens, the factor H binding protein (fH-
bp) and the neisserial heparin binding an-
tigen (NHBA), are each additionally fused 
to a further surface protein to attain bet-
ter stability. The fourth antigen is neisseri-
al adhesin (NadA). Each of these proteins 
is present on meningococci in different 
variants, between which there is only par-
tial immunogenic cross-reactivity. This is 
less pronounced in infants than in elder-
ly persons. For each vaccine component, 
a variant was selected that occurred in a 
high proportion of European meningo-
coccal B strains.
In children aged 2–5 months, 3 vaccine 
doses are recommended by the manufac-
turer for primary vaccination, and 2 vac-
cine doses in all other age groups. A boost-
er vaccination is additionally required for 
children vaccinated in the first 2 years of 
life (see the Summary of Product Charac-
teristics for information on the approved 
vaccination schedules). Study results on 
co-administration with Infanrix hexaÒ, 
Prevenar 7Ò, MMRV in infants and tod-
dlers and with MenveoÒ in adults for the 
most part showed no impairment of im-
munogenicity [35–38]. BexseroÒ can be 
administered simultaneously with the 
following vaccine antigens (as monova-
lent or in combination vaccines): diph-
theria, tetanus, pertussis, Haemophilus in­
fluenzae type b, poliomyelitis (inactivat-
ed vaccine), hepatitis B, heptavalent pneu-
mococci conjugate, measles, mumps, ru-
bella, varicella. To date, there are no data 
available for co-administration with rota-
virus vaccines. BexseroÒ is administered 
as a deep intramuscular injection and is 
contraindicated only in the event of hy-
persensitivity to the vaccine components.
8.1  Vaccine effectiveness
Due to the low incidence of MenB disease, 
the clinical efficacy and effectiveness of 
4CMenB can only be studied in postmar-
keting studies after broad introduction of 
the vaccine. To date, no studies investigat-
ing the effectiveness of 4CMenB by taking 
into account clinical outcomes have been 
published.
8.2  Immunogenicity and 
strain coverage
Currently, the detection of antibodies in-
duced by the vaccine capable of neutraliz-
ing meningococcal B strains in serum in 
the presence of human complement (hS-
BA) is considered a correlate for protec-
tion from the disease [39, 40]. Thus EMA 
accepts meningococcal hSBA at a titer of 
≥ 1:4 as an immunological correlate for 
protection against disease [7].
While the capsule-based meningococ-
cal conjugate vaccines against serogroups 
A, C, W and Y protect against all strains 
expressing the respective serogroup, not 
all circulating MenB strains express at 
least one of the antigens contained in Bex-
seroÒ as a surface protein. The potential 
protection achievable with 4CMenB thus 
depends on what proportion of circulat-
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Fig. 1 9 Incidence of inva-
sive meningococcal disease 
by age and serogroup, Ger-
many, 2010–2013. Insert: 
Age distribution according 
to serogroup
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tigens or cross-protective variants thereof. 
In addition, protection depends on how 
reliably the antibodies that are induced 
by the vaccine actually lead to killing of 
corresponding strains in the hSBA assay. 
With the exception of the specific PorA 
allele, detection of the gene for a surface 
protein does not sufficiently prove that 
this is also expressed by a meningococcal 
strain. Therefore, the so-called Menin­
gococcal Antigen Typing System (MATS) 
was developed to determine the propor-
tion of circulating strains expected to be 
covered by BexseroÒ [41]. MATS is based 
on the detection of the surface proteins 
by ELISA, shown to correlate with kill-
ing of the respective strains in the hSBA 
assay using pooled sera from infants vac-
cinated with 4 doses of 4CMenB. Strains 
with an ELISA value above the protective 
bactericidal threshold (PBT) for a partic-
ular vaccine antigen were killed with high 
probability by hSBA in the pooled sera. 
For Germany, 222 strains from all IMD 
patients diagnosed at the NRZMHi from 
July 2007-June 2008 were analyzed using 
MATS. The results revealed an expected 
overall strain coverage of 82 % [42]. How-
ever, the strain coverage was lower in in-
fants and adults ≥ 25 years of age than in 
1–24-year-old children and adolescents; a 
finding confirmed in an extended anal-
ysis of all 185 strains received from in-
fants with IMD at NRZMHi from July 
2007-June2013 with a strain coverage of 
68 % [43].
The frequency with which the individ-
ual vaccine antigens—alone or in com-
bination—are expressed by the strains 
circulating in Germany is also relevant. 
. Fig. 2 shows that fHbp and NHBA are 
most commonly expressed. Overall, in 
2007–2008 18.9 % of the strains expressed 
none of the vaccine antigens, 27.5 % ex-
pressed only one vaccine antigen (fHbp: 
15.2 %; NHBA: 11.5 %; PorA: 0.5 %) and 
53.9 % expressed at least 2 antigens [42]. 
The expression of more than one antigen 
can theoretically induce a more robust ac-
tivation of complement and may decrease 
the risk for mutations leading to variants 
not susceptible to vaccine-induced anti-
bodies.
The results of MATS analyses must in-
terpreted in the context of the results of 
clinical licensure studies investigating im-
munogenicity. In these studies, vaccine 
antigen-specific hSBA was measured in 
participants before and after vaccination 
with 4CMenB by testing whether strains 
selectively expressing only one of the vac-
cine antigens were killed. Currently, such 
immunogenicity data are still lacking for 
persons ≥ 50 years of age and for those 
with immune deficiencies or immuno-
suppression. For this reason, a systemat-
ic evaluation of immunogenicity for the 
risk groups under consideration here was 
not undertaken. However, a brief sum-
mary of some of the key results regarding 
hSBA responses as observed in the ran-
domized controlled licensure studies for 
individual antigens is presented here.
In the available immunogenicity stud-
ies, study staff responsible for the evalua-
tion of immunogenicity was blinded with 
regard to the vaccines administered. In 
infants, protective antibodies against the 
respective vaccine antigens 1 month after 
administration of 3 doses of 4CMenB at 
2, 4 and 6 months of age [35, 37] were in-
duced in 79–100 % of vaccine recipients 
(see . Annex 1, . Table 3). When the vac-
cine was administered at ages of 2, 3 and 
4 months, the responses were somewhat 
lower, especially for antibodies against 
NHBA [35]. The proportion of children 
with protective titers markedly declined 
prior to administration of a 4th dose at 12 
months of age, especially in children who 
had received 3 doses of vaccine at 1 month 
intervals at ages of 2, 3 and 4 months (see 
. Annex 1, . Table 3). However, after a 
4th dose, hSBA titers ≥ 1:5 were induced 
in 88–100 % of vaccine recipients. In ad-
olescents, 2 doses of 4CMenB achieved 
protective antibodies against all antigens 
(antibodies against NHBA were not mea-































Fig. 2 9 Results of MATS 
(Meningococcal Antigen 
Typing System) analyses on 
222 meningococcal strains 
from IMD patients in Ger-
many from July 2007-June 
2008. MATS results permit 
estimation of the propor-
tion of circulating strains 
expected to be covered by 
4CMenB vaccination (see 
text). The abbreviations 
refer to the vaccine anti-
gens factor H binding pro-
tein (fHbp), neisserial hepa-
rin binding antigen (NHBA), 
neisserial adhesin (NadA) 
and Porin A (PorA), identi-
cal to the New Zealand vac-
cine MeNZB® (PorA NZ)
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Data on immunogenicity at time points 
earlier than 4 weeks after vaccination are 
currently lacking. While data on immu-
nogenicity for infants following a single 
vaccine dose are also lacking, such data 
are available for a small number of one-
year-old children and for adolescents (see 
. Annex 1, . Table 3 and 4). Particular-
ly in toddlers, the immune response after 
one dose was markedly lower than after 2 
vaccine doses or after 4 vaccine doses in 
infancy. In all studies, the protective titers 
in the comparison groups did not increase 
or only increased slightly compared to the 
groups vaccinated with 4CMenB.
Smaller studies [45–47] in infants and 
toddlers, some of which were only pub-
lished in the European Public Assessment 
Report (EPAR) of the EMA [7], showed 
a marked reduction in the proportion of 
vaccine recipients with protective anti-
body titers 12–28 months after vaccination 
with 2–4 doses of vaccine. The extent of 
this reduction varied according to the vac-
cine antigen (see Annex 1, . Table 3). In 
contrast, antibody persistence in adoles-
cents was 82 % 18–24 months after 2 vac-
cine doses for the antigen most commonly 
expressed on German strains, fHbp, [48] 
(see Annex 1, . Table 4). Data on persis-
tence of NHBA antibodies were, however, 
not published in this study.
8.3  Effect on meningococcal 
carriage
Observations after introduction of the 
meningococcal C conjugate vaccines 
in countries such as England, in which 
catch-up campaigns were implemented in 
all children and adolescents, showed that 
MenC vaccination led to a 75 % reduction 
in pharyngeal carriage of serogroup C me-
ningococci [49]. This led to the establish-
ment of herd protection, which plays a key 
role in the ongoing sustained MenC inci-
dence reduction in the United Kingdom 
and in The Netherlands [50, 51]. Wheth-
er 4CMenB has a similar effect on menin-
gococcal carriage could not be conclu-
sively clarified in the only available study 
on this issue [52]. However, herd effects 
would not play a central role for the pro-
tection of the relatively small groups of in-
dividuals at increased risk for IMD under 
consideration here.
8.4  Reactogenicity and safety
The reactogenicity and safety of the 
4CMenB vaccine were evaluated in accor-
dance with the STIKO SOP. The methods 
and results are described in detail in An-
nex 2. No data were identified on safety 
in persons with immune deficiencies/im-
munosuppression. Key results are briefly 
summarized here.
Five randomized studies were identi-
fied for the evaluation of the endpoints 
defined by the responsible STIKO work-
ing group as critical or important. These 
had serious methodological flaws neces-
sitating downgrading of the quality of ev-
idence to “low” or “very low”. Very ra-
re, potentially serious side effects could 
not be evaluated on the basis of insuffi-
cient numbers of included participants. 
These included endpoints classified as 
“critical”, namely seizures, Kawasaki syn-
drome (KS) and hospitalization for in-
fants and toddlers, as well as juvenile ar-
thritis, Guillain-Barré syndrome, seizures 
and acute disseminated encephalomyeli-
tis for adolescents and adults. A total of 3 
cases of confirmed KS occurred in infants 
considered possibly or probably associat-
ed with 4CMenB vaccination in the licen-
sure studies included in our review [35, 
37]. In the adolescent study, 2 cases of ju-
venile arthritis occurred with possible or 
probable association with 4CMenB vacci-
nation [44].
In infants, the available data showed a 
close to 2-fold higher risk for febrile re-
actions when 4CMenB was administered 
simultaneously with the routine vaccines 
Infanrix hexaÒ and PrevenarÒ (> 70 %), 
compared to 40 % after routine vaccines 
alone. An approximately 4- to 5-fold in-
creased risk of severe local pain was also 
observed in infants following 4CMenB (in 
13–29 % of those vaccinated). Fever was 
shown to occur significantly more fre-
quently in adolescents, but not in adults, 
following 4CMenB vaccination (3.7 %) 
compared to placebo (1.6 %). Severe local 
pain and headache occurred significantly 
more frequently in adolescents as well as 
adults following 4CMenB vaccination (see 
Annex 2). The interpretation of results re-
garding the occurrence of fever and pain 
is complicated by the frequent, sometimes 
prophylactic, administration of antipyret-
ics particularly in the infant studies.
The reactogenicity spectrum in the 
week after the vaccination observed in an 
active surveillance study during a vacci-
nation campaign (> 46,000 vaccine recip-
ients aged from 2 months-20 years) in a 
region of Québec in 2014 was comparable 
to that described in licensure studies ([53] 
see also Appendix 2). However, antipyret-
ics were taken prophylactically by > 70 % 
of the vaccine recipients (93 % in < 2-year-
olds). No cases of KS occurred; however 
the statistical power was too low to iden-
tify the occurrence of possible very rare 
adverse reactions in specific age groups.
9  Epidemiology of invasive 
meningococcal diseases 
in risk groups
Specific antibodies and an intact com-
plement system are crucial for the effec-
tive defense against meningococcal infec-
tions [8, 9, 11]. An increased risk of IMD 
was accordingly reported for persons with 
immune deficiencies, among these, par-
ticularly those with complement deficien-
cies [8, 9], but also others, such as persons 
with asplenia [8], persons infected with 
HIV [10, 54, 55] or persons with unre-
placed hypogammaglobulinemia [11]. In 
addition, laboratory staff at risk for con-
tact with N. meningitis aerosols are at in-
creased risk of IMD [4, 5] and IMD inci-
dence is increased in household contacts 
of IMD patients in the ensuing year de-
spite post-exposure chemotherapy [2].
Based largely on available reviews, esti-
mates for the risk of occurrence of IMD in 
the relevant risk groups are described be-
low. Where possible, the incidence of rel-
evant immune deficiencies in the general 
population/in IMD patients was also esti-
mated. In addition, available indirect ev-
idence on expected VE was considered, 
e.g. based on immune responses to oth-
er vaccines. Based on these estimates, the 
number of persons needed to be vaccinat-
ed to prevent one case (NNV) was calcu-
lated for each risk group.
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9.1  Asplenia
9.1.1  Risk of IMD in asplenic 
individuals
The risk of invasive infections such as sep-
sis and meningitis is increased after sple-
nectomy, especially through gram-nega-
tive pathogens, Staphylococcus aureus and 
pneumococci [8, 55–59]. In persons lack-
ing a spleen, these infections can trigger 
the syndrome of Overwhelming postsple­
nectomy infection (OPSI), associated with 
up to 69 % mortality [60]. Based on vari-
ous prospective studies, the risk of IMD 
in asplenic individuals ranged from < 1–
8 cases/100 person years; depending on 
definition and study setting. It was highest 
in the first month after loss of the spleen, 
and remained markedly elevated in first 
1–3 years, decreasing somewhat there-
after [61, 62]. Bisharat et al. [63] report-
ed a mean interval of 23 months between 
splenectomy and the first severe infection 
(range: 0.5–180 months). In patients with 
asplenia due to thalassemia and sphero-
cytosis, severe infections occurred earlier 
than in patients with other causes. They 
occurred latest in patients with traumat-
ic splenectomy.
In the few studies investigating the 
pathogen distribution in infections of as-
plenic patients, meningococci were rare, 
reports ranging from 0–3.7 % of infec-
tions [56–61]. In the 4 available cohort 
studies reporting details of the pathogen 
distribution [56–59], only 4 out of a to-
tal of 1117 severe infections were caused 
by meningococci (0.36 %). If the mean 
overall risk for severe infections in as-
plenic patients is estimated at approxi-
mately 3 severe infections per 100 per-
son years (see above), their risk for IMD 
can be estimated as 3 × 0.0036 × 1000 ≈ 11 
IMD/100,000 asplenic individuals/year. 
Under the assumption that the sero-
group distribution is similar to that of 
the general population, this would cor-
respond to an annual MenB incidence of 
11 × 0.69 = 7.6 ≈ 8 IMD/100,000 asplenic 
individuals/year and an ACWY-incidence 
of 11 × 0.31 = 3.4 ≈ 4 IMD/100,000 asplen-
ic individuals/year. This rather low abso-
lute incidence may be in keeping with the 
observation that no differences were ob-
served in the elimination of intraperitone-
al Nm infection in splenectomized com-
pared to healthy mice [64]. No figures are 
available on the proportion of IMD cases 
in Germany occurring in persons with as-
plenia. In summary, the absolute risk for 
IMD in persons with asplenia appears to 
be only slightly elevated compared to the 
normal population. However, case fatality 
may be markedly increased.
9.1.2  Incidence and prevalence 
of asplenia
According to hospital discharge statistics 
of the Federal Statistical Office, a total of 
8193, 8093, 8113 and 7948 splenectomies 
were performed respectively in the years 
2010–2013 [65]. According to the German 
Asplenia Network [Deutsches Asplenie-
Netzwerk], an estimated 80,000 people 
currently lack a spleen in Germany. Con-
genital asplenia within the context of Iver-
mark syndrome is extremely rare—up un-
til March 2012 one case was registered in 
the German Network for Primary Im-
mune Deficiencies [Deutsches Netzwerk 
für Primäre Immundefekte] (PID) [66].
In addition, certain underlying illness-
es, particularly sickle cell anemia (1000–
1500 patients in Germany [67]) and thal-
assemias (500–600 patients [67]), ma-
lignant hematological diseases such as 
Hodgkin’s lymphoma and chemotherapy 
can lead to functional asplenia. However, 
estimates of number of such patients in 
Germany are generally lacking.
9.1.3  Potential efficacy of MenB 
vaccination in asplenia
Neither the immune response nor the 
clinical efficacy of 4CMenB were stud-
ied thus far in asplenic individuals. Re-
sults from studies on vaccination of as-
plenic individuals with monovalent MenC 
conjugate vaccines [68–70] showed that a 
high proportion (~ 80 %) developed pro-
tective antibody titers, albeit a lower pro-
portion than in healthy volunteers. A sec-
ond dose of vaccine increased the pro-
portion of responders to > 90 %. Howev-
er, the titers attained were lower than in 
healthy vaccinees. Persons with splenec-
tomy due to medical conditions had low-
er vaccine responses than those with sple-
nectomy due to trauma [69]. A review 
[71] of 3 small studies lacking comparison 
groups showed that vaccination of asplen-
ic individuals with heptavalent pneumo-
coccal conjugate vaccines likewise led to 
≥ 4-fold titer increases against 4–5 of the 
7 vaccine antigens in at least half of the re-
cipients. A registry-based study in Canada 
[72] demonstrated a 54 % lower mortali-
ty in asplenic persons who received influ-
enza vaccination compared to those who 
did not.
Thus it seems asplenic individuals are 
to some extent able to mount immune re-
sponses to a number of vaccines, although 
perhaps less well than healthy individuals. 
To what extent this ability can be extrap-
olated to 4CMenB, however, currently re-
mains unclear.
Based on the only slightly elevated 
IMD risk for asplenic individuals, the es-
timated NNV is very high: Under the as-
sumptions of (1) a MenB incidence of 8 
cases of disease/100,000 asplenic individ-
uals/year, (2) a VE of 80 % (lower than the 
95–100 % assumed in healthy persons) 
and (3) a strain coverage of 82 %,
would have to be vaccinated to prevent 
one MenB case in the year after the vacci-
nation. If the duration of protection is as-
sumed to be longer than 1 year, the NNV 
decreases proportionally, e.g. for 3 years it 
would be ~ 6350. The duration of protec-
tion is unknown; it is, however, likely to be 
shorter than in healthy individuals.
Under the assumptions that the inci-
dence of IMD due to MenACWY is 4 cas-
es of disease/100,000 asplenic individuals 
and a VE of 80 % (lower than the ~ 90 % 
observed in healthy older children/ado-
lescents [73]),
would have to be vaccinated to prevent 
one case in the year after the vaccination. 
If duration of protection were 3 years, the 
NNV would fall to 10,400.
NNV=
100 000
8 MenB IMD per 100 000 asplenics
0 80 VE 0 82 Strain coverage
19 000 asplenics
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9.2  Complement deficiencies
9.2.1  Risk of IMD in persons with 
complement deficiencies
A number of complement deficiencies 
are associated with increased IMD risk, 
the most important being deficiencies of 
the terminal components C5-C9. These 
are required for formation of the mem-
brane-attack complex. Compared to per-
sons with an intact complement system, 
the risk for persons with C5-C8 deficien-
cies is estimated to be 7000–10,000-fold 
[74] and for persons with C9 deficiencies, 
1400-fold higher. Approximately half of 
affected persons suffer from IMD repeat-
edly; a prior infection does not appear to 
protect from further infections [9]. Esti-
mates of the lifetime risk for IMD range 
from 39 to 56 % [74–76]. Case fatality, 
however, is markedly lower than in in-
dividuals without complement deficien-
cies, at below 3 % [74, 77], possibly be-
cause fewer cell membrane components 
and toxins are released by the bacteria in 
the absence of the membrane-attack com-
plex [74]. The first episode of IMD in in-
dividuals with terminal complement defi-
ciencies frequently occurs in adolescence, 
markedly later than in persons with intact 
complement [8, 9, 78]. While some case 
series suggest that the rarer serogroups W 
and Y occur more commonly in IMD pa-
tients with late complement deficiencies 
[79–81], IMD patients with and without 
complement deficiencies had similar se-
rogroup distributions in a Dutch study 
[82].
An increased risk for infections with 
encapsulated bacteria has also been re-
ported for persons with C3 deficiency 
or defects in the alternative complement 
pathway (factor D, properdin, factor H) 
[8, 9, 74], although reports of IMD are ra-
re. In patients with properdin deficien-
cies, IMD appears to run a more fulmi-
nant course than in persons with termi-
nal deficiencies, with up to 65 % mortality; 
however the risk of recurrent infections is 
very low [9, 74, 77].
The effect of low concentrations of 
mannose-binding lectins (MBL) or MBL-
polymorphisms on IMD risk appears to 
be minimal. Thus MBL deficiencies were 
observed to be more common in IMD pa-
tients than in controls only in studies in 
which the prevalence of a defective MBL 
gene in the controls was below the expect-
ed value for the general population [9]. In 
the largest case control study published to 
date, this was not the case, and no associ-
ation was found between MBL polymor-
phisms and IMD [83].
Persons with deficiencies of the clas-
sical complement pathway are primari-
ly associated with autoimmune diseases. 
An increased risk for infections (approx-
imately 20 % higher than the background 
risk) has also been described, especial-
ly with encapsulated bacterial pathogens 
(primarily Streptococcus pneumoniae, but 
in rare cases also N. meningitidis) [9, 74, 
78, 84, 85].
9.2.2  Incidence of complement 
deficiencies in Germany
The incidence of congenital complement 
deficiencies varies in different popula-
tion groups and is commonly estimated 
at 0.03 % in available reviews [9, 86] based 
on a study of > 41,000 German conscripts 
born in 1944 [87]. The European registry 
for primary immune deficiencies (PID) 
ascertained a total of 13,708 patients from 
2004–2011 [88]. Of these, 631 had a com-
plement deficiency, the majority (482, 
76 %) C1 inhibitor deficiencies (heredi-
tary angioedema) not associated with an 
increased risk of IMD. Of the remaining 
149 cases (24 %), 57 had deficiencies of the 
classical complement pathway (compo-
nents 1, 2 and 4) (9 %), 4 had C3 deficien-
cies (1 %) and 88 (14 %) had deficiencies 
of the alternative pathway (including the 
terminal components C5–8, factor H and 
factor I, which leads to reduced C3 levels, 
properdin and MBL). Of the included liv-
ing patients with PID, 1.2 % (149/12,340) 
thus had complement deficiencies rel-
evant for IMD. Similarly, only very few 
complement deficiencies were registered 
from 2004 to March 2012 in the German 
PID registry: Of a total of 1232 included 
patients with PID, 13 had complement 
deficiencies, 8 (62 %) of these with defi-
ciencies that could potentially increase 
the risk for IMD [66]. Of all patients with 
PID, 0.65 % (8/1232) thus had comple-
ment deficiencies relevant for IMD. On 
the basis of the patients included in the 
German PID registry, Gathmann et al. 
[66] calculated minimum prevalence es-
timates for all PID in Germany of 1.51 pa-
tients/100,000 Inh., which yielded a prev-
alence of 1.51 × 0.0065 = 0.01/100,000 rel-
evant complement defects or one affect-
ed person per 10 million Inh. However, 
substantial under-reporting must be as-
sumed here, as only approximately half of 
the 43 medical centers identified for the 
care of patients with immune deficien-
cies/immunosuppression had reported 
patients by 2011 and not all patients with 
complement deficiencies are cared for in 
such centers. Even with under-report-
ing by a factor of 10, however, one would 
however arrive at only one case per 1 mil-
lion inhabitants, or approximately 80 cas-
es overall. If one were to take the over-
all prevalence determined by Hässig et 
al. [87] of 0.03 % for all complement de-
ficiencies to estimate the number of af-
fected persons in Germany, one would ar-
rive at an estimated 5904–15,252 affected 
persons in Germany (with the assump-
tion that 24–62 % of all complement defi-
ciencies are associated with an increased 
risk of IMD, see above); therefore around 
10,000 affected persons. An estimate from 
Russia [75] quantified the prevalence of 
people with terminal complement defi-
ciencies at 12/100,000; which would cor-
respond to ~ 9800 affected persons in 
Germany.
In addition, acquired complement de-
ficiencies should be considered in any es-
timate. These are caused either by insuf-
ficient synthesis of complement compo-
nents, e.g. in the case of liver failure, or 
by increased consumption (autoimmune 
diseases, immune complex formation, e.g. 
in the case of systemic lupus erythemato-
sus), or by increased loss (e.g. protein-los-
ing nephropathies) or by pharmacologi-
cal blockade (e.g. through eculizumab, 
which blocks terminal complement acti-
vation through binding to C5 and is used 
for the treatment of paroxysmal noctur-
nal hemoglobinuria (PNH)). Exact fig-
ures on most acquired complement defi-
ciencies are not available. The prevalence 
of PNH in Germany is 13/1,000,000 in-
habitants, so that theoretically up to about 
1000 persons would be under treatment 
with eculizumab [89].
The proportion of IMD patients with 
complement deficiencies was found to 
range from 0 to 50 % in various studies/
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would have to be vaccinated to prevent 
one MenACWY case in the year after the 
vaccination.
9.3  HIV infection
9.3.1  Risk of IMD in persons 
with HIV infection
The incidence of IMD in HIV-infected in-
dividuals in Western countries with estab-
lished antiretroviral therapy has only been 
investigated in a few studies. An increased 
risk of IMD was observed for HIV-infect-
ed individuals in a prospective, active, 
population and laboratory based sur-
veillance study over 5 years (1988–1993) 
in Atlanta (RR = 23.8; 95 % CI: 7.4–74.7) 
[99]. Antiretroviral therapy during this 
period was not yet widely used. In New 
York City, a 10-fold elevated risk of IMD 
was shown for HIV-infected individuals 
through linkage of meningococcal sur-
veillance data with HIV and mortality 
registry data from 2000–2011 [54]. HIV-
infected individuals with IMD had a high-
er probability of having lower CD4+ val-
ues that HIV-infected controls of the same 
age. However, information on the propor-
tion of IMD patients and controls on anti-
retroviral therapy was not available. In this 
study, HIV-infected individuals with IMD 
had lower mortality (10 %) than non-HIV-
infected individuals with IMD (23 %). The 
authors attributed this to more rapid ac-
cess to an infectious diseases specialist 
through regular care within the context of 
HIV disease. In contrast, in a laboratory-
based surveillance study from South Af-
rica HIV-infected individuals had an in-
case series, and was found to be negatively 
correlated with IMD incidence [78].
9.2.3  Potential efficacy of 
4CMenB vaccination with 
complement deficiencies
To date, no studies have been performed 
in which persons with complement defi-
ciencies were vaccinated with 4CMenB. 
In five small, uncontrolled studies per-
sons with terminal complement defi-
ciencies showed increases in capsule-
specific antibodies following vaccina-
tion with bivalent (AC) or tetravalent 
(ACWY) polysaccharide (PS) meningo-
coccal vaccines [90–94] that were com-
parable with [92, 93, 95] or lower [91] 
than those observed in healthy vaccin-
ees. In one study, antibody persistence 
was shorter than in healthy volunteers 
[92]. IMD episodes were observed de-
spite vaccination against the causal sero-
groups in two studies at 2.5–5 years af-
ter vaccination [92, 93]. In addition some 
studies showed an increase in the capac-
ity for serogroup-specific opsonophago-
cytosis of meningococci following vacci-
nation of persons with complement de-
ficiencies with a meningococcal PS vac-
cine [90, 93, 94].
Taken together, the available studies 
suggest a possible benefit of MenACWY 
vaccination for persons with complement 
deficiencies, although randomized, con-
trolled studies are lacking. To what extent 
this might also apply to vaccination with 
the surface protein-based 4CMenB vac-
cine remains to be clarified. Andreoni et 
al. [92] showed that opsonophagocytosis 
of MenC strains in cases of terminal com-
plement deficiency was indeed support-
ed by antibodies against the capsule anti-
gen, but not against subcapsular antigens. 
In contrast, Plested et al. [96, 97] showed 
that serum from a small number of study 
participants vaccinated with an OMV 
vaccine with or without an NHBA com-
ponent and from which C6 was eliminat-
ed supported opsonophagocytosis of me-
ningococcal strains with the same PorA as 
in the OMV components in the presence 
of polymorphonuclear leukocytes. Finally 
Ross et al. [98] postulated a more impor-
tant role for opsonophagocytosis in the 
defense against MenB compared to Me-
nY infections.
If one were to assume a 4CMenB VE 
of 80 % with a strain coverage of 82 %, 
and—particularly applicable for termi-
nal complement deficiencies—a 5000- to 
10,000-fold increased incidence of MenB 
(i.e. 0.31 cases of disease/100,000 Inh. 
× 5000/10,000 = 1550–3100 cases of dis-
ease/100,000 persons with complement 
deficiencies,
100 000
1550 3100 MenB IME per 100 000 Persons with complement defects
NNV=
0 80 VE 0 82 strain coverage
49 98 Personswith complement defects
up to
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would have to be vaccinated to prevent 
one MenB case in the year after the vac-
cination.
Similarly, the risk of IMD through 
MenACWY would be 0.14 ACWY Inh./
year × 5000/10,000 = 700/1400. Therefore, 
with a VE of 80 %
100 000
700 1400 MenACWY IMD per 100 000 Persons with complement defects
NNV=
0 80 VE
89 149 Personswith complement defects
up to
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creased risk (RR: 11.3, 95 % CI: 8.9–14.3) 
for IMD that was associated with in-
creased case-fatality (20 % versus 11 % in 
non-HIV-infected IMD patients, OR = 2.1, 
95%CI: 1.1–3.9) [10]. Taken together, the 
available data suggest that HIV-infected 
individuals are only at slightly increased 
risk for IMD, depending on their immune 
status.
9.3.2  Prevalence and incidence 
of HIV infection
In Germany at the end of 2013 an esti-
mated 80,000 (95 % CI: 69,000–91,000) 
persons were infected with HIV; of these 
~ 65,000 were men, including ~ 53,000 
men who have sex with men (MSM), 
approximately 15,000 were women and 
~ 200 were children. Of these infected in-
dividuals ~ 54,000 were receiving antiret-
roviral therapy (68 %). In 2013, HIV in-
fection was initially diagnosed in approx-
imately 3.500 persons, including 1100 with 
advanced immunodeficiency.
9.3.3  Potential efficacy of a 
4CMenB vaccination 
in HIV infection
A number of studies show lower immune 
responses to MenC or MenACWY con-
jugate vaccines in HIV-infected individ-
uals [100–104]. A recent review conclud-
ed that vaccines in HIV patients general-
ly trigger poorer immune responses than 
in healthy volunteers [105]. Therefore it 
seems likely that the protective effect of 
a 4CMenB vaccination would be weaker 
and of shorter duration for this risk group 
than for healthy persons.
Assuming a 5- to 10-fold increased in-
cidence of IMD in HIV-infected individ-
uals with a VE of 80 % and strain cover-
age of 82 %,
NNV=
MenB IMD per HIV - infectedupto 
100 000
1 5 3 0 100 000
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HIV-infected individuals would need to 
be vaccinated to prevent one case.
The corresponding calculation for 
IMD due to ACWY in HIV-infected in-
dividuals, with a VE of 80 % is
100 000
0 7 up to 1.4) MenB IMD per 100 000 HIV - infected
89,000 to 179,000 persons with HIV-infectioNNV=
0 80 VE
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Thus, the decision whether to vaccinate 
HIV-infected patients should take into ac-
count their immune status and other pos-
sible risk factors for IMD.
9.4  Additional immune 
deficiencies
9.4.1  Risk of IMD in antibody 
deficiency states
As specific bactericidal antibodies play 
a central role in protection against IMD 
[11], it is not surprising that occasional 
evidence is present in the literature for an 
increased risk of IMD in association with 
antibody deficiencies. However, evidence 
is based mainly on case reports that do not 
permit quantification of risk (see review 
in [106]). Patients with antibody deficien-
cies are primarily at risk for respiratory 
infections. Although 2 cases of IMD were 
described in patients with primary anti-
body deficiencies under immunoglobulin 
replacement therapy [106], it seems prob-
able that the risk of IMD in patients re-
ceiving immunoglobulin substitution is 
only minimally elevated compared to the 
normal population [106].
9.4.2  Incidence of antibody 
deficiency states in Germany
Both in the European and in the Ger-
man registry for PID, antibody deficien-
cies comprise the largest group of im-
mune defects, at 52 % [88] and 62 % [66] 
respectively. Among these, common vari-
able immunodeficiency (21 and 37 % of 
all patients respectively) is the most com-
mon. The prevalence of all PID in Germa-
ny, according to a minimum estimate, cor-
responds to 1.51 PID patients/100,000 Inh. 
Assuming the proportion of antibody de-
ficiencies were 62 %, the prevalence would 
be ~ 1 patient/100,000 Inh., or ≈ 800 pa-
tients. In analogy to estimation of the 
prevalence of complement deficiencies 
above, however, this is likely to be an un-
derestimate by a factor of 10–1000.
9.4.3  Potential efficacy of a 
4CMenB vaccination in 
antibody deficiency states
In view of a reduced capacity to produce 
antibodies in this very heterogeneous pa-
tient group, VE is likely to be low [107]. 
However, there appear to be subgroups 
of patients capable of at least transient-
ly generating adequate antibody respons- 
es to the antigens of polysaccharide or 
protein-based vaccines [107–110]. Due to 
the high degree of uncertainty surround-
ing the degree of IMD risk of IMD, the 
NNV was not estimated for this patient 
group. It seems likely, however, that the 
NNV would be similar to that estimated 
for HIV-infected individuals, since the ab-
solute risk for IMD appears only minimal-
ly increased and vaccine effectiveness is 
likely to be low.
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9.5  Recommendation of MenB 
vaccination for individuals with 
certain immune deficiencies/
immunosuppression
As summarized in . Table 1, the risk of 
IMD is markedly increased only in in-
dividuals with complement deficiencies. 
Accordingly, with the exception of this 
risk group, the number of persons that 
need to be vaccinated to prevent one case 
of MenB IMD is very high. In addition, 
the number of cases that can potential-
ly be prevented in the risk groups con-
sidered is very small, again with the ex-
ception of persons with complement de-
ficiencies. However, because of the sever-
ity of IMD and the immunological plausi-
bility for an elevated IMD risk in persons 
with the immune deficiencies/immuno-
suppression considered here, STIKO rec-
ommends both MenACWY and MenB 
vaccination for affected persons based on 
an individual risk assessment.
9.6  Household contacts of 
patients with IMD
9.6.1  Risk of IMD for household 
contacts of IMD patients
Secondary IMD cases can occur in per-
sons following close contact with cases of 
IMD. However, the proportion of IMD 
cases that are epidemiologically linked in 
Germany is very low at < 2 %. Household 
contacts are at highest risk for developing 
IMD. Without chemoprophylaxis, their 
risk within 30 days after contact with the 
index case is up to 1000-fold higher com-
pared to the incidence in the general pop-
ulation [111–113]. According to the results 
of a systematic review, chemoprophylaxis 
reduces the risk of disease for household 
contacts by 84 % (95 % CI, 41–97 %) [113]. 
An estimated 284 persons (95 % CI: 156–
1515) need to be treated (number need­
ed to treat; NNT) to prevent one case. In 
addition, results of a systematic review 
showed that household members are at 
increased risk of IMD in the 14–365 days 
following contact with index case even af-
ter receiving chemotherapy, estimated at 
1.08 IMD/1000 household members [2]. 
The majority (71 %) of observed second-
ary cases, however, occurred within 14–
90 days after contact with the index case. 
It was estimated that one IMD case can 
be prevented through vaccination with 
a MenACWY conjugate vaccine if 1033 
(95 % CI; 638–1678) household contacts 
receive serogroup-specific vaccination in 
addition to chemotherapy [2]. These es-
timates were based on the assumptions 
that vaccination occurs within 7 days af-
ter contact, immunity develops within 7 
days following vaccination and VE is 85–
95 %. STIKO recommended post-expo-
sure vaccination of unvaccinated house-
hold (-like) contacts in addition to che-
moprophylaxis if the disease of the index 
patient was caused by serogroups A, C, 
W or Y in 2009. Vaccination should take 
place as soon as possible following con-
tact [3].
In England & Wales, Ladhani et al. in-
vestigated whether household contacts of 
IMD cases might benefit from MenB vac-
cination with BexseroÒ in addition to che-
moprophylaxis for the prevention of sec-
ondary IMD [114]. The NNV for MenB 
vaccination was calculated based on the 
risk of subsequent IMD cases as estimat-
ed by Hoek et al. [2] described above. Be-
cause the calculated NNV against MenB 
was higher than for the ACWY vaccina-
tion in most scenarios, routine post-ex-
posure vaccination of household contacts 
of MenB cases was not recommended in 
England & Wales [115].
9.6.2  Potential efficacy of a 
4CMenB vaccination 
to prevent secondary 
cases in household 
contacts of IMD cases
Currently, it is not routinely possible to 
investigate promptly whether a menin-
gococcal B strain responsible for a case 
of IMD is covered by the vaccine using 
MATS. As the decision on vaccine pro-
phylaxis has to be made quickly, for the 
time being the vaccination series would 
have to be initiated as soon as the strain 
is identified as serogroup B, knowing 
~ 20 % of strains would not be covered by 
4CmenB. Furthermore, data on immuno-
genicity following a single dose of 4CMenB 
are only available for children aged 1 year 
or older. These reveal a markedly poor-
er hSBA response after one dose in one-
year-old children [116, 124] than in infants 
following 4 doses or adolescents follow-
ing one or two doses (see above and An-
nex 1, . Table 3). In addition, data on the 
dynamics of the antibody increase in the 
2 weeks following vaccination were not 
available.
Because of these uncertainties, the 
NNV for vaccination of household con-
tacts with BexseroÒ was calculated for a 
range of probable VE. In a favorable sce-
nario that might apply to older children 
and adults in which the MenB vaccine 
is administered within 4 days after diag-
nosis of the index case (assuming that by 
then the causative serogroup in the in-
dex case has been identified), the vaccine 
is assumed to protect with a VE of 90 % 
against 82 % of the strains from 14 days af-
ter vaccination and the disease risk is 108 
IMD cases/100,000 household contacts 
[2], an estimated.
would have to be vaccinated to prevent 
one MenB case. When a lower VE of 50 % 
is assumed, as might apply to infants, the 
estimated NNV increases to 2258. Tak-
ing into account the lower strain coverage 
in infants of 68 % (see above) would fur-
ther increase the NNV to 2723. The NNV 
would also increase if vaccination were 
undertaken later than 4 days after diagno-
sis of the index case. Thus, although a pre-
cise estimate is not possible based on cur-
rently available evidence; the effectiveness 
of post-exposure vaccination with Bexse-
roÒ is likely to be lower than that of Men-
ACWY conjugate vaccines.
In view of the severity of IMD, STIKO 
recommends vaccination of household 
contacts of serogroup IMD cases based 
on an individual risk assessment despite 
the likely lower VE of BexseroÒ com-
pared to the conjugate vaccines. Besides 
the possibility that the household might 
be situated in a social setting with ongo-
ing circulation of pathogenic meningo-
cocci, family members might also have 
a genetic predisposition for an increased 
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9.7  Laboratory staff
Cases of IMD in laboratory staff have rare-
ly been described and almost always in as-
sociation with non-compliance of recom-
mended safety precautions (class II safe-
ty workbench; respiratory protection in 
cases of aerosol formation) [4, 5, 117–120]. 
Two studies [4, 5] estimated IMD risk 
in laboratory staff compared to the risk 
in the general population. In the USA, 6 
cases were identified during a global sur-
vey from 1996 to 2000, corresponding to 
an annual incidence of 13 cases of dis-
ease/100,000 laboratory employees. In the 
same period, an IMD incidence of 0.3 was 
observed in 30–59-year-old persons (rel-
ative risk (RR) = 43). An incidence of 271 
IMD cases/100,000 person years (95 % CI: 
88–634) was estimated based on 5 IMD 
cases in laboratory staff in England and 
Wales from 1985 to 1999, compared to a 
background incidence of 1.47 (RR = 184 
(95 % CI 60–431).
Thus, for vaccination of microbiology 
laboratory staff working with N. menin­
gitidis, assuming 95 % VE after 2 doses of 
Bexsero, it can be calculated that
100 000
13 up to 271) 0.69 MenB IMD per 100 000 laboratory workers
NNV= 3 years (duration of protection) 229 to 4770 laboratory workers









Considering the severity of the disease 
and that laboratory accidents can never be 
completely avoided, STIKO recommends 
MenB vaccination of laboratory staff at 
risk of exposure to N.­meningitis aerosols.
10  Vaccination strategy
Vaccination with BexseroÒ can potential-
ly protect risk groups from IMD due to 
serogroup B. Persons with terminal com-
plement deficiencies are at highest risk 
of IMD, while the absolute risk for per-
sons with asplenia, HIV-infected individ-
uals (especially on antiretroviral therapy) 
or with other immune deficiencies is on-
ly slightly higher than that of the gener-
al population.
Household contacts of patients with 
IMD caused by serogroup B can also po-
tentially benefit from MenB vaccination, 
however to a lesser extent than house-
hold contacts of index cases with IMD 
caused by serogroups ACWY. Since over 
two thirds of secondary cases that occur in 
contacts despite their having received che-
moprophylaxis occur in the 3 months fol-
lowing contact with the index case, rapid 
serogroup determination is crucial to en-
able appropriate postexposure vaccination 
as promptly as possible.
STIKO likewise recommends vaccina-
tion of occupationally exposed persons 
with a MenB vaccine.
The relevant risk groups and physi-
cians involved in their care should be spe-
cifically informed about this vaccine, e.g. 
via patient networks and through profes-
sional societies. In addition, however, the 
lack of data on clinical efficacy, the incom-
plete strain coverage and the availability 
of only rough estimates of IMD risk in 
persons with various immune deficien-
cies or immunosuppressive states should 
also be communicated. Finally, the dura-
tion of the potential vaccine protection is 
also unknown; therefore no advice can be 
given at present as to whether (or when) a 
booster vaccination is required.
11  Implementation/feasibility
Household contacts, occupationally ex-
posed individuals and persons with im-
mune deficiencies/Immunosuppression 
should be vaccinated according to the li-
censed vaccination schedule, as described 
in the Summary of Product Characteris-
tics. In addition it appears prudent not to 
administer 4CMenB simultaneously with 
other vaccinations if possible, at least in in-
fants and toddlers. Although simultane-
ous vaccination with Infanrix hexaÒ, Pre-
venar7Ò and MMRV did not compromise 
the immunogenicity of these vaccine an-
tigens in licensure studies, the risk for lo-
cal and systemic side effects, especially for 
fever, was markedly higher in infants and 
toddlers than with separate administration. 
Simultaneous administration of antipyret-
ics reduced the risk for fever in infants and 
toddlers without compromising the immu-
nogenicity of 4CMenB or the mentioned 
routine vaccines [116]. Evaluation of data 
from an active surveillance study within the 
scope of a 4CMenB vaccination campaign 
in Québec, however, revealed that prophy-
lactic antipyretics had no effect on the risk 
of fever in children above 4 years of age.
In view of the severity of this disease, 
acceptance for MenB vaccination by per-
sons at increased risk of disease can be as-
sumed to be very high.
12  Evaluation of the vaccination 
recommendation
As the ascertainment of IMD in risk 
groups is not generally established, the 
would have to be vaccinated to prevent 
one case depending on the assumed in-
cidence (see above). The corresponding 
calculation for MenACWY would be:
100 000
13 up to 271) 0.31MenACWY per 100 000 laboratory workers
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detection of a possible decrease in IMD 
burden attributable to MenB vaccination 
will be difficult to identify. MenB cases 
occurring after introduction of BexseroÒ, 
should, however, be thoroughly investi-
gated. In particular, in the case of menin-
gococcal B disease in a vaccinated per-
son, it is essential to clarify whether the 
responsible strain should have been cov-
ered by the vaccine or not. This can on-
ly be tested using MATS to determine 
the expression of vaccine antigens at the 
national reference laboratory NRZMHi 
(www.meningococcus.de), i.e. with a test 
currently available only from the vaccine 
manufacturer. Additionally required sero-
logical testing to differentiate between pri-
mary versus secondary vaccine failure (i.e. 
absent or insufficient neutralizing anti-
bodies due to an insufficient primary vac-
cine response versus waning immunity) 
can also be performed at NRZMHi. Active 
laboratory surveillance after broader use 
of the vaccine is also important to iden-
tify possible immune­escape­variants that 
might spread in the case of altered popu-
lation immunity.
The Risk Management Plan (RMP) as 
outlined by EMA specifies that the risk for 
anaphylaxis/anaphylactic shock, Kawasa-
ki syndrome, seizures and febrile seizures, 
Guillain Barré syndrome (GBS) and acute 
disseminated encephalomyelitis (ADEM) 
after 4CMenB vaccination should be eval-
uated more precisely in a post-licensure 
observational safety surveillance study 
(V72_36OB) by the end of 2018 at the lat-
est [7]. As 4CMenB vaccination has thus 
far not been implemented within a routine 
vaccination program (routine infant vac-
cination is expected to commence in Eng-
land and Wales in September 2015), this 
study has not yet commenced. Further-
more, the RMP calls for performance of a 
study on safety, tolerability and immuno-
genicity in persons with complement defi-
ciencies. Such studies would also be desir-
able in persons with additional immuno-
deficiencies and/or immunosuppression 
and should also specifically investigate the 
duration of immune protection.
The current Summary of Product 
Characteristics for BexseroÒ specifies 
that the vaccine is subject to additional 
monitoring to ensure rapid identification 
of any safety issues. Health profession-
als in Germany are required to report ev-
ery suspected case of an adverse reaction 
due to BexseroÒ to the Paul Ehrlich In-
stitute (PEI). According to § 6 para. 1, no. 
3 IfSG, all suspected cases of health im-
pairment exceeding the usual severity of 
a vaccination reaction should be report-
ed to the PEI. This applies regardless of 
whether or not a vaccination recommen-
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 Annex 1
Key results on immunogenicity of 4CMenB (BexseroÒ) vaccination as reported in licensure studies
Table 3 Immunogenicity after 4CMenB vaccinations in infancy and toddler age: % of study participants with a hSBA titer≥ 1:5 (1:4)
% with hSBA titer ≥ 1:5 (1:4)
fHbp (%) NHBA (%) NadA (%) PorA-NZ (%)
Infants—priming
Pre-vaccination (n = ~ 1320) 3 33 4 1
1 month after 3 doses (2,4,6 monthsR, n = ~ 1282) [37]a 100 84 100 84
1 month after 3 doses (2,4,6 monthsR, n = ~ 525) [35] 99 ND 99 79
1 month after 3 doses (2,4,6 months, n = ~ 525) [35] 99 ND 99 86
1 month after 3 doses (2,3,4 monthsR, n = ~ 270) [35]a 99 37 100 82
1 month after 3 doses (2,3,4 monthsR, n = ~ 165) [116] 100 ND 99 78
Infants pre-booster
6 months after 3 doses (2,4,6 monthsR, n = ~ 435) [37]a 81 61 99 22
8 months after 3 doses (2,3,4 monthsR, n = ~ ~ 246) [7] 58 25 97 19
8 months after 3 doses (2,3,4 monthsR, n = ~ 70–140) [116] 53 ND 97 12
Post-booster (1-year-olds)
1 month after 4 doses (2,4,6,12 monthsR, n = ~ 425) [37]a 100 95 100 97
1 month after 4 doses (2,3,4,12 monthsR, n = ~ 70–140) [116] 100 ND 100 88
1 month after 3 doses (6,8,12 months, n = 22–24)  [121] 100 ND 100 96
Toddlers
1 month after 1 dose at 12 months of age (n = 22)  [124] 73 ND 73 18
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 Annex 2
Evaluation of the reactogenicity and safety of the 4CMenB vaccine (BexseroÒ)
13  Methods
To perform a systematic review of the re-
actogenicity and safety of 4CMenB vac-
cine, we defined “PICO” (Population, In­
tervention, Comparator and patient rele­
vant outcomes) according to the recom-
mendations of the Grading of Recom­
mendations Assessment, Development and 
Evaluation (GRADE) working group. Per-
sons of all ages were defined as the pop-
ulation for inclusion, vaccination with 
4CMenB was defined as the intervention, 
vaccination with placebo or with anoth-
er vaccine or no vaccination were defined 
as comparators. Outcomes were classified 
according to their importance for decision 
making, using a scale of 1–9. Outcomes 
rated from 7 to 9 and 4 to 6 were classified 
as “critical” and “important”, respectively. 
In infants and toddlers, fever, seizures, Ka-
wasaki syndrome and hospitalization for 
clarification/treatment of adverse events 
(AE) were classified as critical outcomes. 
Severe local pain and vomiting were clas-
sified as important outcomes. In adoles-
cents and adults, seizures, Guillain-Barré 
syndrome (GBS), juvenile arthritis (JA), 
seizures and acute disseminated encepha-
lomyelitis (ADEM) were classified as crit-
ical, and fever, severe local pain and head-
ache as important. The working group de-
cided to define a temperature threshold 
for comparing intervention and compar-
ator groups after taking into account the 
location of temperature measurements 
and thresholds used in available studies 
retrieved in the literature search.
Relevant studies published since 2010 
addressing outcomes classified as “crit-
ical” or “important” were identified ac-
cording to evidence-based criteria in a 
systematic literature search via the DIM-
DI portal using the searchstring “f ((MenB 
vaccin? or 4CMenB or Bexsero) or (me-
ningococc? and (serogroup B) and (vac-
cin? or immuni?ation))) AND PY > 2009”.
The literature search was performed us-
ing the following databases: Cochrane, 
MEDLINE, EMBASE, SciSearch, GLOB-
AL Health, BIOSIS Previews.
Two reviewers independently screened 
the titles and abstracts of the retrieved ref-
erences. All full texts of publications con-
sidered relevant by at least one of the two 
reviewers were examined in detail and a 
Table 4 Immunogenicity after 1 or 2 doses of 4CMenB in adolescence: % of study participants with a hSBA-titer ≥ 1:4
% with hSBA titer ≥ 1:4
fHbp (%) NHBAa (%) NadA (%) PorA-NZ (%)
Pre-vaccination (n = ~ 1471) 44 88 34 35
1 month after 1 dose (n = 318) 92 ND 95 93
1 month after 2 doses 1 month apart, n = 222)c 100 100 100 100
1 month after 2 doses 2 months apart, n = 215)c 100 100 100 100
18–24 months after 2 dosesb,d (n = 257) 82 ND 94 77
ND No data available.
an = 46.
bIntervals of 1, 2 or 6 months between doses.
cSantolaya et al. 2012 [44].
dSantolaya et al. 2013 [48].
Table 3 Immunogenicity after 4CMenB vaccinations in infancy and toddler age: % of study participants with a hSBA titer≥ 1:5 (1:4) (Continued)
% with hSBA titer ≥ 1:5 (1:4)
fHbp (%) NHBA (%) NadA (%) PorA-NZ (%)
1 month after 1 dose at 12 months of age (n = ~ 70)  [116] 85 ND 93 23
1 month after 1 dose at 40 months of age (n = 39) [47]c 72 62a 87 23
1 month after 2 doses at 40 months of age (n = 39)  [47] 100 72 100 90
Persistence in infants & toddlers
12 months after 4 doses (2,4,6,12 monthsR, n = 291–299)  [7]a 62 36 97 17
28 months after 4 doses (2,4,6,12 monthsR, n = 17)  [46]b 65 67 76 41
28 months after 3 doses (6,8,12 months, n = ~ 15)  [47]c 36 79 100 14
20 months after 4 doses (6,8,12,40 months, n = ~ 9)  [45] 67 45 100 17
20 months after 2 doses (40, 42 months, n = ~ 23)  [45] 38 83 100 0
ND No data available.
R Concomitantly with routine vaccinations.
an = 70–100 for NHBA.
bOf 43 newly-recruited controls of the same age, 0–3 % had hSBA titers ≥ 1:5 for PorA and NadA; 63 % for fHbp; 68 % for NHBA.
cOf 40 newly-recruited controls, < 3 % had hSBA-titers ≥ 1:4 for fHbp, NadA and PorA and 53 % for NHBA.
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consensus then reached regarding their 
inclusion.
Relevant data were systematically ex-
tracted using a standardized form, and 
the internal and external validity of the 
included studies assessed. Data pertain-
ing to outcomes classified as “critical” or 
“important” were extracted from the stud-
ies and entered into the Review Manage-
ment Software Review Manager (Version 
5.2, The Nordic Cochrane Centre, The Co­
chrane Collaboration, 2014). When data 
were available from several studies with-
out significant heterogeneity these were 
pooled for meta-analysis. The data were 
imported into the computer software 
GRADEprofiler (version 3.6) to create 
a GRADE evidence profile that was also 
used for calculation of the risk differenc-
es. The quality of evidence of all includ-
ed studies was assessed for each outcome 
according to the following criteria: study 
design, heterogeneity, precision, indirect 
evidence, strength of effect and publica-
tion bias. The lowest quality of evidence 
for any of the critical outcomes was used 
to classify to overall level of quality of the 
evidence.
14  Results
14.1  Systematic literature search
A total of 576 abstracts were retrieved in 
our literature search after removal of du-
plicates. Screening of the titles and ab-
stracts led to identification of 25 poten-
tially relevant publications [35, 37, 44– 
48, 116, 121, 122, 124–137]. Of these, 5 ful-
filled the inclusion criteria [35, 37, 44, 116, 
128]. . Fig.  3 shows the results of the lit-
erature search as a flowchart. None of the 
included studies reported on the safety of 
4CMenB in persons with an increased risk 
for invasive meningococcal disease (IMD) 
related to underlying medical conditions.
14.2  Description of 
included studies
All five studies included in the review of 
reactogenicity and safety were random-
ized controlled studies funded by Novar-
tis Vaccines. With the exception of a sub-
study in [37] and the adolescent study 
[44], the study participants (or their par-
ents) knew which vaccines were admin-
istered. Blinding may also have been in-
complete in the adolescent study since 
the study staff administering the vaccines 
was aware of the group assignments. Key 
aspects of the studies included in this re-
view are summarized in . Tables 5 and 
6. As data was not available in all stud-
ies on all outcomes classified as “impor-
tant” or “critical”, we considered further, 
related outcomes for descriptive analy-
sis: Thus, in addition to hospitalization, 
we looked at the outcome “Medical treat-
ment for vaccination reactions” (see . Ta-
ble 5 and 6). In addition, we considered the 
outcome “Administration of antipyretics 
and analgesics”, as we considered this rel-
evant for the interpretation of the data on 
febrile reactions and pain. Data on some 
of the outcomes classified as critical were 
not or only incompletely addressed in the 
5 included studies– sometimes presum-
ably because they did not occur. For in-
stance, studies did not report consistent-
ly on how long after vaccination the few 
reported seizures occurred. In addition 
differentiation between febrile and non-
febrile seizures was not always clear. For 
these reasons, and because study sizes did 
not permit assessment of very rare AE, it 
was not possible to evaluate the outcomes 
seizures, KS, hospitalizations for AE, JA, 
GBS and ADEM based on GRADE. Rele-
vant available data were therefore not in-
cluded in the GRADE profile, but only 
listed in . Tables 5 and 6.
Data on the outcomes fever, severe lo-
cal pain and vomiting in infants and tod-
dlers were included in the GRADE profile 
[35, 37]. Both studies allowed comparison 
between reactogenicity after 4CMenB 
plus routine vaccinations versus after rou-
tine vaccinations alone at the ages of 2, 4 
and 6 months. Vesikari et al. [37] present-
ed the number of study participants who 
had experienced the respective safety out-
come after at least one of the received vac-
cine doses, while Gossger et al. [35] pre-
sented the number of events per dose ad-
ministered. Because the incidence of the 
safety outcomes after each of the three 
doses in the Gossger study was similar 
(see . Fig. 4), only the number of events 
after the 1st dose were considered in the 
review to enable use of the same denom-
inator (number of study subjects and not 
number of all administered doses) for data 
from both studies. In addition, the study 
by Gossger et al. [35] permitted the com-
parison between 4CMenB alone at ages of 
2, 4 and 6 months and routine vaccina-
tions alone at ages of 3, 5 and 7 months. In 
Vesikari et al. [37], a fourth 4CMenB dose 
was also administered at age 12 months 
with or without MMRV, but without a 
comparator group. The objective of the 
3rd, much smaller study by Prymula et al. 
[116], was to evaluate the immunogenici-
ty and reactogenicity of 4CMenB + rou-
tine vaccines with and without prophylac-
tic administration of paracetamol; thus an 
appropriate comparator group was lack-
Potentially relevant references from
DIMDI- literature search (Cochrane, MEDLINE,
EMBASE, SciSearch, GLOBAL Health, BIOSIS Previews)
References including titles and abstracts 
(n= 576)   





Exclusion of unsuitable references
after screening of titles and
abstracts (n=551) 
Exclusion of unsuitable references after full-text
screening; (n=20) 
−    Abstracts related to studies later published as peer-
       reviewed full-text papers (n=4)
−    Studies lacking control groups (n=8)
−    Study lacking safety data (n=1) 
−    Study with former MenB-vaccine formulation (n=1)
−    Content irrelevant (n=6)
Fig. 3 8 Flowchart of the literature search for the review of safety and reactogenicity of the 4CMenB 
vaccine (Bexsero®)
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Study Gossger et al. 2012 [35] Vesikari et al. 2013 [37] Prymula et al. 2014 [116]
Study design Phase 2b, open-label RCT Phase 3 RCT with non-blinded and observer-blindeda 
groups; both comparing three 4CMenB batches
Non-blinded phase 2 RCT
NCT NCT00937521 NCT00657709; NCT00847145 NCT00937521
Study period August 2008-July 2010 03.31.2008–08.16.2010 July 2009-November 2010
Study locations Belgium, UK, Germany, Italy and 
Spain






4CMenB + R (see below) at age 2, 
4, 6 months; 4CMenB alone at age 
2, 4, 6 months and R at age 3, 5, 7 
months; 4CMenB+R at age 2, 3, 4 
months
Observer-blindeda: 4CMenB + R at age 2, 4, 6 months;
Not blinded: 4CMenB + R at age 2, 4, 6 months
At age 12 months: 4CMenB-vaccinated children from 
both study arms randomized for receiving 4CMenB-
booster +/− MMRV
At age 2, 3, 4, 12 months: 4CMenB 
+ R or 4CMenB + R + prophylactic 
paracetamol. At age 13 months: 






R at ages 3, 5, 7 months Observer-blinded: R + MenC at age 2, 4, 6 months
Not blinded: R alone at age 2, 4, 6 months
MenC conjugate vaccine (Menju-
gate®, Novartis Vaccines) + R at age 
2, 3, 4 months. 4CMenB + R at age 
12 and 4CMenB at age 13 months
Age at study entry 2 months 2 months 2 months
Study size Total 1885 Total: 3630 Total: 558
Follow-up Recording of AE and SAE in a paper 
diary for 7 days after each vaccina-
tion with telephone support from 
the study team. Documentation 
of all SAE up to 6 months after the 
last 4CMenB dose
Recording of pre-defined and all observed AE for 7 
days after each vaccination. Any SAE or events requir-
ing medical treatment were documented for the entire 
study period
Recording of adverse events and 
SAE for 7 days after each vaccination
Definitions and available data on occurrence of PICO outcomes
Fever ≥ 38.0 °C (axillary) ≥ 38.5 °C (rectal) ≥ 38.0 °C (rectal)
Severe local pain Crying when injected limb was 
moved +/− refusal to move the 
extremity
Crying when injected limb was moved Crying when injected limb was 
moved
Vomiting No formal definition, but data 
available
No formal definition, but data available No formal definition, but data avail-
able
Seizures No formal definition: 1 febrile sei-
zure 2 days after 4CMenB vaccina-
tion alone (1/626), 1 seizure after 
4CMenB vaccination alone (1/626); 
1 seizure after R alone (1/626); 1 
seizure after 4CMenB + R (1/941)
No formal definition. After the first 3 doses of vac-
cine in infants: 2 febrile seizures < 24 h after the 2nd 
vaccine dose of 4CMenB + R (2 seizures/2478 doses, 
possibly associated); 2 additional seizures with fever 
(1x only lower limbs affected, in one case only one 
arm) < 24 h after 1st 4CMenB + R (2 seizures/2478 
doses possibly associated). No seizures after only R or 
R + MenC. 13 additional seizures with fever 9 days—6 
months after 4CMenB + R or 4CMenB + MMRV, which 
were classified as not associated with the vaccination
No formal definition: No febrile or 
afebrile seizures were observed
Kawasaki syn-
drome (KS)
No formal definition. 2 KS cases 
reported after receiving 4CMenB; 
one possibly associated (no further 
details e.g. on time intervals)
Fever > 5 days with at least 4 of the 5 major criteria 
for the diagnosis of KS (rash, cervical lymphadenopa-
thy, bilateral conjunctival injection, changes in the 
oral mucosa, changes in the peripheral extremities. 
Patients, who did not exhibit all criteria but showed 
abnormalities of the coronary arteries consistent with 
KS likewise fulfilled the case definition. Cases fulfilling 
only some of the criteria were classified as incomplete 
KS. 2 confirmed KS cases were reported 3 and 7 weeks 
and one incomplete case 14 weeks after 4CMenB + 
R vaccination. One confirmed case was reported 23 
weeks after a MenC vaccination
KS not reported in study
Hospitalization Number of hospitalizations (6 per 
1567 doses of 4CMenB +/− R) due 
to fever < 2 days after 4CMenB 
vaccinations, further data not 
provided
No information No information
Table 5 Description of studies included in the review of safety and reactogenicity of the 4CMenB vaccine in infants
1331Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 11-12 · 2015 | 




No information In the non-blinded sub-study medical treatment for 
fever was reported for 28/1966 (1.4 %) infants after 
4CMenB + R vaccination and in 12/659 (1.8 %) after R 
vaccination alone. In the observer-blinded sub-study, 
these proportions were 26/493 (5.3 %) and 13/470 
(2.8 %—for R + MenC)
Medical treatment for fever was 
reported in 9 cases after 855 
doses of 4CMenB alone (1.1 %); in 2 
cases after 700 doses of 4CMenB + 
paracetamol (0.3 %), in 4 cases after 




No information 2302/2478 (93 %) after 4CMenB + R; 471/659 (71 %) 
after R alone
Following 4CMenB vaccination, 
36–55 % of 4CMenB recipients 
who had not received prophy-
lactic paracetamol were given 
paracetamol therapeutically (no 
further details provided)
R Routine vaccines: Infanrix hexa® plus Prevenar7®, MMRV Measles, Mumps, Rubella-Varicella-vaccination, (S)AE (serious) adverse events.
aObserver-blinded: In study-arm, parents and study staff, with the exception of staff who administered the vaccine, were blinded regarding the administered vaccine 
(4CMenB vs. MenC).
Table 6 Description of the studies included in the review of safety and reactogenicity of the 4CMenB vaccine in adolescents and adults
Study Santolaya et al. 2012/adolescents Read et al. 2014/adults
Study design Phase 2b/3, placebo-controlled, randomized, observer-
blindeda study
Phase 3, placebo-controlled, randomized, observer-
blinded study
NCT NCT00661713 NCT01214850
Study period June 2008-December 2010 September 2010-December 2011
Study locations Santiago and Valparaíso, Chile England
Intervention group: 4CMenB 
vaccination schedule
4CMenB (0, 1, 2, 6 months, total of 2–3 doses) 4CMenB (0, 1 months)
Comparator group: Vaccine 
and vaccination schedule
Placebo (aluminum hydroxide) (0, 1, 2, 6 months) First comparator group: 1st dose MenACWY-CRM (Men-
veo®) and 2nd dose placebo (aluminum hydroxide) (0, 1 
months)
Second comparator group: Ixiaro®(0, 1 months)
Age at study entry 11–17 years (mean: 13.8 years) 18–24 years
Study size Total: 1631 Total: 2968 (subset of n = 600 for safety evaluation)
Follow-up Recording of local and systemic vaccination reactions in 
a paper diary for 7 days after each vaccination, and SAEs 
throughout the entire study period
Recording of local and systemic vaccination reactions in 
a paper diary for 7 days after each vaccination, and SAEs 
throughout the entire study period
Definitions and available data occurrence of PICO outcomes
Fever ≥ 38.0 °C (axillary) ≥ 38.0 °C (kind of measurement not described)
Severe local pain Severity of pain was assessed using a predefined scale 
from mild (noticeable) to severe (interference with normal 
activities)
No formal definition
Headache Severity of pain was assessed using a predefined scale 
from mild (noticeable) to severe (interference with normal 
activities)
No formal definition
Seizures No formal definition; 1 convulsion reported after 1st dose 
of 4CMenB in participant with paternal history of epilepsy
No formal definition/no data
Juvenile arthritis No formal definition/two cases of juvenile arthritis, one 
case evaluated as possibly and one case as probably associ-
ated with 4CMenB (170 days and 198 days after the third of 
the 3 doses of 4CMenB)
No formal definition/no data
GBS No formal definition/no data No formal definition/no data
ADEM No formal definition/no data No formal definition/no data
Hospitalization No information No information
Medical treatment due to vac-
cination reactions
Medical treatment due to fever (4CMenB: < 1 %, 4/1480), 
(placebo: < 1 %, 2/1290)
No information
Administration of antipyretics 
and analgesics
Use of antipyretics: (4CMenB: 4 %, 61/1461), (placebo: 2 %, 
22/689), p < 0.0002)
Therapeutic use of antipyretics: (4CMenB: 20 %, 75/375), 
(placebo: 6 %, 11/175); prophylactic use of antipyretics: 
(4CMenB: 4 %, 16/372), (placebo: 1 %, 2/172);
aObserver-blinded: Vaccine recipients, parents, and study staff, with the exception of staff who administered the vaccine, were blinded.
Table 5 Description of studies included in the review of safety and reactogenicity of the 4CMenB vaccine in infants (Continued)
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ing and the study could not be included 
in our evaluation. None of the 3 studies 
allowed a comparison between 4CMenB 
alone and placebo, which would have 
been necessary for a completely unbi-
ased description of the reactogenicity of 
4CMenB.
A single study each in adolescents [44] 
and adults [128] was included for evalu-
ation of the outcomes fever, severe local 
pain and headache after administration of 
2–3 doses of 4CMenB alone versus pla-
cebo. In the adult study, one compara-
tor group received 2 doses of the Japanese 
encephalitis vaccine IxiaroÒ. The other 
comparator group received the quadri-
valent meningococcal conjugate vaccine 
as a first dose and placebo as a 2nd dose. 
Therefore, safety outcomes observed in 
recipients of the 2nd 4CMenB dose were 
compared with those observed in recipi-
ents of the placebo dose.
14.3  Evaluation of the 
reactogenicity and 
safety of 4CMenB in 
infants and toddlers
The results of the two studies included 
for evaluation of reactogenicity and safety 
outcomes in infants and toddlers showed 
that vaccination with 4CMenB+ rou-
tine vaccinations was associated with in-
creased reactogenicity, particularly due to 
fever. Compared to vaccination with rou-
tine vaccines alone, the risk for fever, se-
vere local pain and vomiting was signifi-
cantly increased (see Forest plots . Fig. 5 
and GRADE profile . Table 7). Because 
of significant heterogeneity of the abso-
lute frequencies and relative and absolute 
risks for severe pain as well as for vomit-
ing in Vesikari et al. [37] and in Gossger et 
al. [35] (see below) the data for these out-
comes were not pooled. Fever following 
4CMenB+ routine vaccinations occurred 
very frequently after 4CMenB plus rou-
tine vaccines (in 74 % of the vaccine dos-
es), but only after 40 % of the vaccine dos-
es with routine vaccinations alone. Thus 
if 1000 infants were to receive 4CMenB+ 
routine vaccinations, 335 (95 % CI: 254–
419) more febrile reactions would occur 
than in 1000 children receiving routine 
Study or Subgroup Events
4CMenB+Infanrix hexa Infanrix hexa
Events Total Total Weight
Risk Ratio
M-H, Random, 95% CI
Risk Ratio
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Favours [experimental] Favours [control]
0.1 1 10 100
Outcome: Vomiting 
Outcome: Severe pain at the injection site 
Outcome: Fever ≥38°C (axillary) 
Fig. 4 8 Forest plots showing relative risks for reactogenicity and safety outcomes in infants and toddlers receiving 4CMenB 
plus routine vaccines (Infanrix hexa® plus Prevenar®) versus routine vaccines alone) according to the 1st, 2nd or 3rd vaccine 
dose based on data from Gossger et al. [35]
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vaccines only. Severe pain also occurred 
more frequently after 4CMenB + routine 
vaccinations than after routine vaccina-
tions alone (see . Fig. 5 and . Table 7), 
but to a greater extent in the study by Vesi-
kari et al. (29.2 vs. 7.7 %) than in the study 
by Gossger et al. (13.3 vs. 2.6 %). Vomiting 
occurred more frequently after 4CMenB+ 
routine vaccinations than after routine 
vaccinations alone only in the study by 
Vesikari et al. (26.7 vs. 17.5 %, see . Fig. 5 
and . Table 7).
The definition for high fever varied in 
the included studies. In Gossger et al. [35] 
11.5 % (72/624) of infants developed an ax-
illary temperature of ≥ 39.0 °C after the 1st 
dose of 4CMenB + routine vaccinations 
in the 7 days following vaccination, while 
this was the case in only 3.5 % (11/311) of 
infants who received routine vaccinations 
alone (RR = 3.26, 95 % CI: 1.76–6.06; risk 
difference (RD) = 100/1000, 95 % CI: 80–
130). In Vesikari et al. [37] 1.2 % of infants 
developed a rectal temperature ≥ 40.0 °C 
after at least one of the doses of 4CMenB 
+ routine vaccinations in the 6 h following 
the vaccination while this was the case for 
none (0/659) of the children who received 
routine vaccinations alone (RR = 15.77, 
95 % CI: 0.96–257.78); RD = 10/1000, 95 % 
CI: − 10–30). In addition to varying tem-
perature thresholds and observation pe-
riods in the two studies, the frequent re-
ceipt of antipyretics in Vesikari et al. (see 
. Table 5) might also explain the more 
seldom occurrence of high fever; howev-
er data on receipt of antipyretics are lack-
ing in Gossger et al.
Data from Gossger et al. [35] also per-
mitted a comparison between infants who 
were vaccinated with 4CMenB only and 
infants vaccinated with routine vaccina-
tions only. For this comparison, the risk 
of fever after the 1st dose of 4CMenB was 
38.0 % (238/627), still significantly high-
er than after routine vaccinations (30.9 % 
(96/311) RR = 1.23, 95%CI: 1.01–1.49). 
The absolute risk was, however, markedly 
lower than with concomitant vaccination 
(74 %, see above). After 4CMenB alone 
the risk for severe pain in the vaccinated 
extremity was 10.2 % (64/626), also signif-
icantly higher than after routine vaccina-
tions alone (2.6 % (8/310) RR = 4.0, 96 % 
CI 1.9–8.2). This absolute risk of 10.2 % as 
well as the risk difference (76/1000, 95 % 
CI: 47–106), were, however, somewhat 
lower than for the comparison of con-
comitant vaccination with routine vac-
cines alone (13.3 % and 110/1000, respec-
tively, see . Fig. 5 and . Table 5). No sig-
nificant difference was observed in the oc-
currence of vomiting after 4CMenB alone 
and routine vaccinations alone (14.2 vs. 
13.6 %). Although the evidence from these 
two studies was rated low quality due to 
a number of methodological weaknesses 
(see below), these results do suggest that 
4CMenB vaccination of infants is associ-
ated with higher reactogenicity as shown 
in the more frequent occurrence of local 
pain and fever than vaccination with rou-
Study or Subgroup Events 
4CMenB+Infanrix hexa Infanrix hexa
Events Total Total Weight
Risk Ratio
M-H, Random, 95% CI
Risk Ratio
M-H, Random, 95% CI
Study or Subgroup Events 
4CMenB+Infanrix hexa Infanrix hexa
Events Total Total
Risk Ratio
M-H, Random, 95% CI
Risk Ratio
M-H, Random, 95% CI
Study or Subgroup Events 
4CMenB+Infanrix hexa Infanrix hexa
Events Total Total
Risk Ratio
M-H, Random, 95% CI
Risk Ratio
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0.01
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0.01
Favours [experimental] Favours [control]
0.1 1 10 100
Outcome: Fever ≥38°C
Outcome: Severe pain at the injection site 
Outcome: Vomiting 
Fig. 5 8 Forest plots showing relative risks (RR) for reactogenicity and safety outcomes in infants and toddlers receiving 
4CMenB plus routine vaccines (Infanrix hexa® plus Prevenar®) versus routine vaccines alone)
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tine vaccines. The reactogenicity of con-
comitant vaccination with 4CMenB + 
routine vaccinations was higher still, re-
flected particularly in a high rate of febrile 
reactions that occurred in over 70 % of 
vaccinated infants. In both studies, tem-
perature peaked after 6 h and had normal-
ized 2 days after vaccination in the major-
ity of cases [35, 37].
The evidence quality of all considered 
outcomes was downgraded by one level 
in the included infant studies due to indi-
rectness (simultaneous administration of 
other vaccinations as well as lack of place-
bo comparison). In addition, the reactoge-
nicity outcomes were measured/observed 
by the parents. Together with their knowl-
edge of what vaccines their child received 
(with the exception of a subgroup of par-
ents in Vesikari et al.; in this case, however, 
the vaccinating staff was not blinded), this 
increased the risk of bias and therefore 
led to downgrading of the evidence qual-
ity for all outcomes by an additional lev-
el. Finally, the studies showed major het-
erogeneity for the outcomes “severe local 
pain” and “vomiting” (I2 = 84 % and 79 % 
respectively). Thus the data could not be 
pooled and the quality of evidence was 
further downgraded for these outcomes. 
The overall evidence underlying the re-
view for infants and toddlers was there-
fore rated as “low” (see . Table 7).
The 3 additional outcomes seizures, 
Kawasaki syndrome and hospitaliza-
tion, all rated as critical, were not includ-
ed in a GRADE profile for reasons out-
lined above (and see . Table 5). Data on 
medical consultations (. Table 5) for fe-
ver were available in Vesikari et al. and re-
vealed a lower treatment rate in the non-
blinded than in the observer-blinded sub-
study. The medical consultation rate for 
fever after 4CMenB plus routine vacci-
nations was higher (5.3 %) than after rou-
tine vaccinations plus MenC vaccination 
(2.8 %, p = 0.07 (Fischer exact) only in the 
observer-blinded sub-study. Although 
febrile convulsions or seizures with fe-
ver were reported more frequently after 
4CMenB (+/− routine vaccines) than af-
ter routine vaccines (see . Table 5), the 
small number of observed febrile convul-
sions after 4CMenB vaccination does not 
suggest a highly elevated risk of seizures 
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ever, the frequent receipt of paracetamol 
could have influenced the risk for sei-
zures. Furthermore, to ensure sufficient 
power for detection of increased risk for 
very rare AE, a much higher case number 
would have been necessary. Consequently, 
as detailed in the Risk Management Plan 
(RMP), EMA requires more precise inves-
tigation of the risk for anaphylaxis/ana-
phylactic shock, Kawasaki syndrome, sei-
zures and febrile seizures in a post­licen­
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Fig. 7 8 Forest plots showing relative risks (RR) for reactogenicity and safety outcomes in adults receiving 4CMenB versus pla-
cebo
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14.4  Evaluation of the 
reactogenicity and safety 
of the 4CMenB vaccine in 
adolescents and adults
The 2 studies with results on reactoge-
nicity and safety in adolescents [44] and 
adults [128] were considered separately 
because they were conducted on different 
continents, there was no overlap in the 
ages of the enrolled study subjects, and 
the reported frequencies of reactogenici-
ty outcomes differed markedly. In the ad-
olescent study, safety outcomes were pre-
sented as the total number of events in re-
lation to the total number of vaccine dos-
es administered and not, as in the other 
studies, in relation to the number of vac-
cinated study subjects. Thus vaccine dos-
es administered to the same study par-
ticipant were regarded as independent 
events, effectively tripling case numbers 
and leading to unduly narrow confidence 
intervals.
Fever, severe local pain and headache 
occurred significantly more frequent-
ly compared to placebo vaccination after 
4CMenB vaccination in adolescents, while 
in adults this applied only to the latter two 
outcomes (see . Fig. 6 and 7; . Tables 8 
and 9). As in the infant studies, the use of 
antipyretics was relevant to the interpre-
tation of febrile reactions in the studies: 
In the adult study [128], 4 % of vaccine re-
cipients took antipyretics prophylactical-
ly for the 1st dose of 4CMenB and 9 % for 
the 2nd dose and a further 19 and 21 %, 
respectively, took antipyretics therapeuti-
cally. For the placebo dose, 3 % took an-
tipyretics prophylactically and 6 % thera-
peutically. In the adolescent study [44] an-
tipyretic use was reported by 4 and 2 % of 
the adolescents vaccinated with 4CMenB 
or placebo, respectively. This difference 
possibly explains the higher rate of fe-
ver after the 4CMenB vaccination in ad-
olescents (3.7 %) vs. adults (1.9 %). In any 
case, at < 4 %, the rates of fever in ado-
lescents and adults were very much low-
er than in infants. Severe local pain al-
so occurred somewhat less often than in 
infants, following 16.9 % (adolescents) of 
4CMenB doses in adolescents and in 8.3 % 
of adults. Again, the lower incidence of se-
vere pain in the adult study might be due 
to their more frequent use of antipyretics. 
The risk differences between the 4CMenB 
and the placebo groups were markedly in-
creased in both adolescents and adults for 
severe pain (131 and 64 more events/1000 
vaccinations) and headache (with 154 and 
91 more events/1000 vaccinations, see 
. Tables 8 & 9).
In addition to fever, local pain and 
headache seizures, GBS and ADEM, and 
JA were also classified as critical outcomes 
for older children and adults when PICO 
were defined. Of the latter four, only sei-
zures and JA were mentioned in the two 
available studies [44, 128]; thus presum-
ably none of the other 2 safety outcomes 
was observed. In the 1622 adolescents vac-
cinated with ≥ 1 dose of 4CMenB, 1 con-
vulsion was observed in a participant after 
the first 4CMenB dose; this participant re-
ported a family history of epilepsy. In ad-
dition, also in the adolescent study, 2 cas- 
es of JA occurred 170–198 days following a 
3rd dose of 4CMenB; in the 1st case, joint 
pain and tendinitis had occurred once be-
fore in the past. No cases occurred after 
placebo vaccination. A causal association 
with the vaccine was therefore assessed 
by the authors as possible for the 2nd case 
and probable for the 1st. A much larger 
study would be necessary to demonstrate 
a statistically significant association. It 
should be noted in this context, howev-
er, that arthralgia occurred after approxi-
mately 24 % of the administered 4CMenB 
doses, but only after approximately 13 % 
of the placebo doses (percent values tak-






SAEs possibly or 
probably related to 
vaccination
SAEs related to 4CMenB (routine vaccina-
tions were also sometimes administered 
in parallel)




Total: n = 1877 (4CMenB, at 
least one dose: n = 1567/
Routine vaccination (Infanrix 
hexa® + PCV7): n = 310
n = 20 (detailed infor-
mation on 18 cases)
2 seizures (of these 1 febrile seizure); 1 HHE; 1 
Kawasaki syndrome; 6 hospitalized children 
with fever within 2 days after vaccination; 1 
aseptic meningitis; 1 retinal dystrophy (prob-
ably congenital); 1 synovitis of the right hip; 1 
transient hearing loss; 1 transient apnea
2 seizures; 1 HHE
Vesikari [45] (2013) 
Infants and toddlers
Total: n = 3628 (4CMenB at 
least 1 dose: n = 2480/Routine 
vaccination (Infanrix® + PCV7 
or MenC: n = 1148)
n = 19 (detailed infor-
mation on 11 cases)
2 febrile seizures, 2 seizures with simultane-
ous fever; 2 confirmed Kawasaki syndromes 
(3 and 7 weeks after 4CMenB vaccination; 1 
case of blindness in association with micro-
cephaly; 1 case of pyrexia
1 febrile seizure (9 days 
after 4CMenB + MMRV, 
possibly related to 
MMRV vaccination);
Prymula [117] 
(2014) Infants and 
toddlers
Total: n = 538 (4CMenB at least 




Total: n = 1759 (4CMenB at 
least 1 dose: n = 1631/Pla-
cebo: n = 128)
n = 2 2 x juvenile arthritis
Read (2014) [44] 
Adults
Total: n = 1959 (4CMenB at 
least 1 dose: n = 974/Placebo; 
n = 985)
n = 3 1 dyspnea, 1 hand tremor, 1 thyroiditis
HHE hypotonic hyporesponsive episodes.
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en from . Fig. 5 taken in [44]). Additional 
serious adverse events (SAE) observed in 
the studies are listed in . Table 10.
The quality of evidence of the adoles-
cent study was downgraded by one level 
due to the increased risk of bias present 
due to non-blinding of the personnel ad-
ministering the vaccines. Because the re-
actogenicity outcomes were presented in 
relation to the total number of doses and 
not to study subjects, the quality of evi-
dence was further downgraded to “low”, 
due to indirectness.
Since in the adult study only 600 study 
participants were included for observa-
tion of reactogenicity and safety, confi-
dence intervals for the RR pertaining to 
the outcomes fever and headache were 
very wide (and spanned 1 for fever) due 
to low event counts. Therefore, the qual-
ity of evidence was downgraded due to 
imprecision. Due to an additional elevat-
ed risk of bias attributed to non-blinding 
of the study personnel administering the 
vaccines, quality of evidence was further 
downgraded to “low” for all outcomes.
In the Risk Management Plan, EMA 
stipulated that—in addition to the afore-
mentioned safety-relevant outcomes of 
anaphylaxis/anaphylactic shock, Kawa-
saki syndrome, seizures and febrile sei-
zures for infants and toddlers—the risk of 
GBS and ADEM after 4CMenB vaccina-
tion should be evaluated more precisely 
by means of a post­licensure observational 
safety surveillance study (V72_36OB) [7].
15  Postmarketing Surveillance
No publications reporting on postmar-
keting surveillance of BexseroÒ follow-
ing licensure were identified in the liter-
ature search. However, through commu-
nication with colleagues, a report on ac-
tive surveillance of possible AE follow-
ing a vaccination campaign in Saguenay-
Lac-St-Jean, Québec (Canada) with long-
standing increased incidence of MenB 
IMD caused by a ST-269 meningococ-
cal B clone was identified. AE were ascer-
tained in the 7 days following MenB vacci-
nation in 0–20-year-old persons. [53]. Of 
43,740 persons who had received a dose of 
4CMenB in May and June 2014, 28 % com-
pleted a questionnaire on the occurrence 
of AE. The primary objective of the sur-
vey was to determine in real time the fre-
quency of absences from work/school/day 
care and medical consultations attribut-
able to the vaccine in the 7 days after vac-
cination. In addition, the questionnaire 
was designed to ascertain the frequency 
of vaccine-related fever, the effect of pro-
phylactic antipyretics on the risk of fever, 
febrile convulsions and severe arthral-
gias. Finally, the influence of AE on the 
responders’ intention to obtain the second 
dose of BexseroÒ was investigated. Active 
surveillance was supplemented by the al-
ready established passive surveillance sys-
tem for the reporting of adverse drug re-
actions, through which physicians were 
legally obliged to report, all unusual clini-
cal manifestations following vaccinations.
The interpretation of the reported AE 
must take into account that antipyretics 
(most commonly as paracetamol) were 
taken prophylactically by 70 % of all study 
subjects. Use of antipyretics was highest at 
93 % in vaccine recipients under 2 years 
of age, and declined with age to 43 % in 
> 17-year-olds.
In participants of the active surveil-
lance study, fever within 7 days after 
4CMenB vaccination occurred in 10.9 % 
of vaccine recipients; most often in 
< 2-year-olds at 14 %, followed by 12 % in 
2–4-year-olds and 6.8 % in older children 
and adolescents. In < 2-year-olds, fever 
occurred more often when 4CMenB was 
administered concomitantly with other 
vaccines (19 vs. 13 %, p = 0.09). The inci-
dence of fever following the 4CMenB vac-
cination in children < 2 years of age was 
lower in those who had taken antipyret-
ics than in those who had had not: 14 % 
versus 31 % in 2–11-month-old children 
and 13 versus 23 % in 2–11-month-olds, 
p < 0.001. Two or more doses of antipyret-
ic led to a greater reduction than only one 
dose, but only in children under 2 years 
of age. In children aged 5 and over, an-
tipyretics were no longer associated with 
a reduction in the occurrence of fever. In 
children < 2 years of age with co-adminis-
tration of other vaccines, fever was report-
ed in 7/11 (64 %) children who had not 
received any antipyretics, in 22/64 (34 %) 
who had received one dose of antipyretics 
and in 38/268 (14 %) who had received ≥ 2 
doses (p < 0.001). The highest mean tem-
perature was 38.9 °C and did not vary sig-
nificantly with age. Less than 1 % reported 
fever ≥ 40.5 °C (rectal). The median dura-
tion of fever was 2 days. One febrile con-
vulsion was recorded in a 1-year-old child 
through active surveillance and an addi-
tional febrile convulsion in a 6-month-old 
child through passive surveillance in a to-
tal of 3886 with children < 2 years of age 
vaccinated with 4CMenB. This was few-
er cases than expected based on the inci-
dence of febrile convulsions in the licen-
sure studies after 4CMenB. The almost 
universal prophylaxis with antipyretics 
may have played a role here.
Arthralgia was reported by 113 vac-
cine recipients; however, following con-
tact with a nurse, only 5 of these were rat-
ed as severe. None of these were associ-
ated with warmth, reddening or swell-
ing, signs suggestive of arthritis. Howev-
er, the observation period was too short to 
exclude the occurrence of later-onset ar-
thritis with certainty.
Absenteeism of the vaccine recipient 
or their carers due to fever, malaise or lo-
cal side effects that occurred within 7 days 
after vaccination were reported by 6.0 % 
of responders and 1.2 % reported having 
consulted a physician because of an AE 
in this time interval. In addition, 4 hos-
pitalizations > 24 h duration were report-
ed after the 1st 4CMenB dose, but none 
apparently causally associated with the 
vaccine. Of all responders, 99 % report-
ed that they intended to receive the 2nd 
4CMenB vaccination dose, but this pro-
portion was lower among those who had 
reported medical consultations or absenc-
es due to the 4CMenB vaccination at 92 %.
No cases of GBS, ADEM or Kawasaki-
syndrome (KS) were ascertained through 
the active or the the passive surveillance 
system. As the authors discuss, however, 
with only 12,500 vaccinated children ≤ 5 
years of age, an expected KS incidence in 
Saguenay-lac-St. Jean of < 8/100,000 chil-
dren ≤ 5 years of age and the short obser-
vation time in both surveillance systems, 
the power of the study was insufficient 
to exclude a slightly increased risk of KS 
through the vaccine [53].
Further results on the monitoring fol-
lowing additional 4CMenB vaccine dos-
es in Saguenay-Lac-St-Jean were present-
ed in the final report of the active sur-
veillance study [139]. The observations 
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after a 2nd dose of BexseroÒ differed as 
follows from those after the 1st dose: Fe-
ver occurred more frequently (11 vs. 9 %, 
p < 0.001). While after the 1st dose, vac-
cine recipients taking antipyretics report-
ed fever 49 % less frequently than vaccine 
recipients who had not taken antipyret-
ics, after the 2nd dose this the case for on-
ly 35 % of those taking antipyretics. Ab-
sences or medical consultations due to AE 
occurring in the 7 days after vaccination 
were reported more frequently after the 
2nd dose (9.0 %) than after the 1st dose 
(6.0 %). After the 2nd dose, there were 4 
reported hospitalizations, for conditions 
possibly related to the vaccine: One case 
of anaphylaxis following concomitant 
vaccination with hepatitis A vaccine and 
BexseroÒ and one febrile convulsion fol-
lowing vaccination with BexseroÒ.
Since availability of BexseroÒ in Ger-
many, a total of 770 AE were reported to 
PEI on 218 vaccine recipients via the pas-
sive reporting system, including 8 seizures 
(of these 4 febrile convulsions) and one 
anaphylactic shock reaction. No signifi-
cant safety signals for BexseroÒ were de-
tected in the routine analyses performed 
at PEI on AE reports after vaccinations 
(Keller, May 2015, personal communi-
cation).
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